3,4-Dihydrophthalazine-1(2H)-ketone derivatives and preparation method and use thereof
By developing 3,4-dihydrophthalazine-1(2H)-one compounds as CRBN regulators, the serious side effects of thalidomide drugs have been solved, and the efficient treatment of multiple myeloma has been achieved, which is significantly better on existing drugs and reduce toxic side effects.
Patent Information
- Application Number
- CN202310656044.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-05
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-06-05
AI Technical Summary
Existing thalidomide drugs have serious side effects in the treatment of cancers such as multiple myeloma, which limits their effectiveness and drug resistance. A new CRBN modulator is urgently needed to optimize performance and improve side effects.
Develop a 3,4-dihydrophthalazine-1(2H)-one compound as a protein-targeted degrader (PROTAC) for CRL4CRBN E3 ubiquitin ligase, which generates a variety of proteins by recruiting endogenous proteins and degrading them. physiological activities to prevent and treat multiple myeloma and other cancers.
This compound effectively inhibits the growth of multiple myeloma cells, is significantly better than existing drugs, and shows lower toxic side effects in in vivo experiments, providing a safer and more efficient treatment plan.
Smart Images

Figure CN116655591B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a 3,4-dihydrophthalazine-1(2H)-one compound and its structural derivatives, its pharmaceutically acceptable salt, prodrug, stable isotope derivative, isomer, solvate or polymorph, and its preparation method and use as a medicine. The compound can be used as a regulator of targeted ubiquitination, especially for the treatment of diseases related to CRBN protein. Background Art
[0002] Thalidomide and its structural derivatives, lenalidomide and pomalidomide, are called immunomodulators (IMiDs). Thalidomide was originally marketed in Germany as a sedative, but was banned due to its strong teratogenic effects. Scientists later discovered that it can effectively relieve the symptoms of patients with erythema nodosum leprosy and inhibit the expression of tumor necrosis factor in the treatment of leprosy. Thalidomide, lenalidomide and pomalidomide have been approved by the FDA for the treatment of multiple myeloma patients. Many studies have confirmed that CRBN (Cereblon) is the target of this type of immunomodulator.
[0003] CRBN is a "substrate receptor" for E3 ubiquitin ligase. After IMiDs act on CRBN, they can activate E3 ubiquitin ligase, causing substrate proteins to be rapidly ubiquitinated and recognized and degraded by the proteasome. Studies have shown that immunomodulators such as lenalidomide regulate CRL4 in multiple myeloma cell lines. CRBN The anti-tumor effect is achieved by inhibiting the function of E3 ubiquitin ligase. After the immunomodulator acts on CRBN, it will prompt E3 ubiquitin ligase to recruit substrate proteins such as IKZF1 / IKZF3 and mark them with ubiquitin, resulting in the recognition and degradation of IKZF1 / IKZF3 and other proteins by the 26S proteasome. The degradation of IKZF1 and IKZF3 directly reduces the expression of transcription factors such as IRF4 and Myc, thereby producing cytotoxic effects on myeloma cells; on the other hand, the degradation of IKZF1 and IKZF3 increases the expression of IL-2 in T cells, thereby activating the immune response of T cells and inhibiting the function of B cells, achieving tumor killing and tumor proliferation inhibition.
[0004] Studies have shown that different immunomodulators have different substrate protein degradation characteristics after binding to CRBN protein. For example, when treating multiple myeloma, lenalidomide mainly achieves its therapeutic effect by selectively degrading IKZF1 and IKZF3; while in the treatment of myelodysplastic syndrome (del(5q)MDS), it mainly achieves its therapeutic effect by degrading CK1α. With the development and clinical trials of new immunomodulators, the indications of thalidomide, lenalidomide and pomalidomide are also expanding. For example, FDA-approved thalidomide is used to treat erythema nodosum leprosy, lenalidomide is used to treat prostate cancer in clinical trials, and pomalidomide is used to treat myelofibrosis in clinical trials.
[0005] However, imidazoles have many side effects. The prescription information of lenalidomide clearly states that the drug has the risk of bone marrow suppression, deep vein thrombosis, pulmonary embolism and teratogenicity. During clinical trials, imidazoles showed obvious hematological toxicity, which required a dose reduction in patients. That is, although lenalidomide has beneficial activity, its effectiveness is limited by the significant side effects. Therefore, there is an urgent need for a new and efficient CRBN regulator in this field, which can optimize the performance of existing imidazole IMiDs on the one hand and improve the severe drug resistance problem on the other. Summary of the invention
[0006] The present invention describes a preparation method and use of a 3,4-dihydrophthalazine-1(2H)-one compound, which can recruit endogenous proteins to E3 ubiquitin ligase and degrade them, and produce various physiological activities related to substrate proteins through protein degradation, thereby effectively preventing, improving and treating cancer diseases such as multiple myeloma; the compound of the present invention is used for CRL4 CRBN Protein targeted degraders (PROTACs) related to the preparation of ligands of E3 ubiquitin ligases.
[0007] The present invention relates to a compound represented by formula (I), a pharmaceutically acceptable salt, a prodrug, a stable isotope derivative, an isomer, a solvate or a polymorph thereof:
[0008]
[0009] in:
[0010] X1 is N or CH; n is 1 or 2;
[0011] R1 is selected from H, C 1-10 Straight or branched alkyl, C 3-10 Cycloalkyl;
[0012] S / D is a single bond or a double bond, and when it is a double bond, R1 does not exist;
[0013] R2 and R3 are independently selected from H, D, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, -S-alkyl, -CN, -NO2, -N3, -CH(Ph)2, perfluoroC1-C4 alkyl and perfluoroC1-C4 alkoxy, -NR4R5, -OR4, -COR4, -CO2R4, -CONR4R5, -C(=NR4)NR5R6, -NR4COR5, -NR4CO2R5, -SO2R4, -NR4SO2NR5R6 or -NR4SO2R5;
[0014] R4, R5, and R6 are each independently H, D, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl; wherein (R4 and R5) and / or (R5 and R6) together with the atoms to which they are attached can each form a ring selected from optionally substituted or unsubstituted cycloalkyl, saturated or unsaturated heterocycle, aryl and heteroaryl.
[0015] In certain embodiments, the substituents and chemical bonds in formula (I) are preferably selected from the following:
[0016] (a) X1 is CH, n is 2;
[0017] (b) R1 is CH3;
[0018] (c) R2 is H;
[0019] (d) S / D is a single bond;
[0020] (e) R3 is independently selected from H, D, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, -S-alkyl, -CN, -NO2, -N3, -CH(Ph)2, perfluoroC1-C4 alkyl and perfluoroC1-C4 alkoxy, -NR4R5, -OR4, -COR4, -CO2R4, -CONR4R5, -C(=NR4)NR5R6, -NR4COR5, -NR4CO2R5, -SO2R4, -NR4SO2NR5R6 or -NR4SO2R5;
[0021] R4, R5, and R6 are each independently H, D, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl; wherein (R4 and R5) and / or (R5 and R6) together with the atoms to which they are attached can each form a ring selected from optionally substituted or unsubstituted cycloalkyl, saturated or unsaturated heterocycle, aryl and heteroaryl.
[0022] In certain embodiments, in formula (I), R3 is further preferably selected from the following: independently selected from H, D, halogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, -S-R4, -CN, -NO2, perfluoro C1-C4 alkyl and perfluoro C1-C4 alkoxy, -NR4R5, -OR4, -COR4, -CO2R4, -CONR4R5, -C(=NR4)NR5R6, -NR4COR5, -NR4CO2R5, -SO2R4, -NR4SO2NR5R6 or -NR4SO2R5;
[0023] R4, R5, and R6 are each independently H, D, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl; wherein (R4 and R5) and / or (R5 and R6) together with the atoms to which they are attached can each form a ring selected from optionally substituted or unsubstituted cycloalkyl, saturated or unsaturated heterocycle, aryl and heteroaryl.
[0024] In certain embodiments, in formula (I), R3 is further preferably selected from the following: independently selected from H, D, halogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, -S-R4, -CN, -NO2, perfluoro C1-C4 alkyl and perfluoro C1-C4 alkoxy, -NR4R5, -OR4, -COR4, -CO2R4, -CONR4R5, -C(=NR4)NR5R6, -NR4COR5, -NR4CO2R5, -SO2R4, -NR4SO2NR5R6 or -NR4SO2R5;
[0025] R4, R5, R6 are each independently H, D, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, saturated or unsaturated heterocyclic group, aryl or heteroaryl; wherein (R4 and R5) and / or (R5 and R6) together with the atoms to which they are attached can each form a ring as shown in formula (II),
[0026]
[0027] wherein X2 is selected from NH or CH2 or O;
[0028] Ring A is a 5-6 membered aromatic ring containing 0-3 heteroatoms N, S or O;
[0029] R7 is selected from H, D, halogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl;
[0030] R8 is selected from H, D, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, -S-alkyl, -CN, -NO2, -N3, -CH(ph)2, perfluoro C1-C4 alkyl and perfluoro C1-C4 alkoxy, -NR9R 10 , -OR9, -COR9, -CO2R9, -CONR9R 10 , -C(=NR9)NR9R 10 ,-NR9COR 10 ,-NR9CO2R 10 , -SO2R9, -NR9SO2NR 10 R 11 Or -NR9SO2R 10 ;
[0031] R9, R 10 , R 11 Each is independently H, D, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, saturated or unsaturated heterocyclic, aryl or heteroaryl; wherein (R9 and R 10 ) and / or (R 10 and R 11 ) together with the atoms to which they are attached, each may form a ring selected from optionally substituted or unsubstituted cycloalkyl, saturated or unsaturated heterocycle, aryl and heteroaryl.
[0032] In certain embodiments, the ring represented by formula (II) is further preferably selected from:
[0033] Ring A is a benzene ring;
[0034] R7 is H;
[0035] X2 is NH;
[0036] R8 is a structure represented by formula (III):
[0037]
[0038] Wherein the B ring is an N-substituted non-aromatic ring selected from any of the following structures:
[0039]
[0040] R 12 is H, D, halogen, -CN, -NO2, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl; wherein the alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl, if substituted, is optionally substituted with at least one substituent R 13 Replaced by R 13 It is halogen, lower alkyl, lower alkoxy, cyano or nitro.
[0041] In certain embodiments, in formula (III), ring B is a piperazine ring preferably substituted by a lower alkyl, alkene, alkyne, halogen, nitro, etc., or a substituted piperazine of formula (IV):
[0042]
[0043] Wherein the C ring is a 5-6 membered aromatic ring, containing 0-3 heteroatoms N, S or O aromatic heterocyclic rings;
[0044] R 14 is H, D, halogen, lower alkyl, lower alkoxy, cyano, nitro or hydroxy;
[0045] n=0, 1, 2, 3, 4 or 5.
[0046] Another aspect of the present invention is to provide a pharmaceutical composition, which includes a compound shown in formula (I), a pharmaceutically acceptable salt, prodrug, stable isotope derivative, isomer, solvate or polymorph thereof, and one or more pharmaceutically acceptable carriers or excipients. The pharmaceutically acceptable carriers or excipients include, but are not limited to: ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins such as human albumin, buffer substances such as phosphates, glycerol, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, beeswax, and lanolin.
[0047] The present invention also relates to a combination drug, which includes a compound represented by formula (I), a pharmaceutically acceptable salt, prodrug, stable isotope derivative, isomer, solvate or polymorph thereof and at least one additional drug, wherein the at least one additional drug is a chemotherapeutic agent or an immunomodulator (such as an immune checkpoint inhibitor, a tyrosine kinase inhibitor, a proteasome inhibitor, an antibiotic, an alkylating agent, an antimetabolite, a hormone drug, an immunoactive agent, an interferon-type active agent and a mixed active agent).
[0048] The present invention also relates to a compound represented by formula (I), or a pharmaceutically acceptable salt, prodrug, stable isotope derivative, isomer, solvate or polymorph thereof, or a pharmaceutical composition thereof, for use in the preparation of a pharmaceutical composition for treating and / or preventing diseases related to CRL4. CRBN Use of the invention in a medicine for treating diseases related to E3 ubiquitin ligase. Preferably, the diseases include, but are not limited to, cancer, pain, nervous system diseases, and immune system diseases.
[0049] The present invention also relates to the use of the compound represented by formula (I) or its pharmaceutically acceptable salt, prodrug, stable isotope derivative, isomer, solvate or polymorph or drug combination in the preparation of a drug for treating and / or preventing cancer diseases, wherein the cancer diseases include but are not limited to: various types of leukemia, multiple myeloma, various malignant lymphomas such as non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, erythema nodosum, autoimmune diseases such as systemic lupus erythematosus, myelodysplastic syndrome, breast cancer, digestive tract cancer, various types of lung cancer, liver cancer, pancreatic cancer, skin cancer, head and neck cancer, melanoma, uterine cancer, ovarian cancer, various endocrine gland cancers, kidney or ureter cancer, one or more of CNS tumors.
[0050] The compound of the present invention, its pharmaceutically acceptable salt, prodrug, stable isotope derivative, isomer, solvate, polymorph or pharmaceutical composition thereof, can be administered by suitable routes, such as oral, sublingual, rectal, parenteral, injection (intradermal, subcutaneous, intramuscular, intravenous, arterial injection), lung, nose, tongue, cheek, skin, mucosa, conjunctiva, topical administration or administration in the form of implant.
[0051] The compound represented by formula (I) of the present invention or its pharmaceutically acceptable salt, prodrug, stable isotope derivative, isomer, solvate or polymorph can be used as CRL4 CRBN Ligands of E3 ubiquitin ligases are used to prepare related protein targeted degraders (PROTACs).
[0052] The present invention also relates to the use of the compound represented by formula (I) or its pharmaceutically acceptable salt, prodrug, stable isotope derivative, isomer, solvate or polymorph in the preparation of protein targeted degradation agent (PROTAC). Preferably, the compound or its pharmaceutically acceptable salt, prodrug, stable isotope derivative, isomer, solvate or polymorph is used as CRL4 CRBN Ligands of E3 ubiquitin ligases are used to prepare protein targeted degraders (PROTACs).
[0053] The present invention also relates to a synthetic method for preparing a compound of formula (I), which can be synthesized using commercially available raw materials by known methods. In the specific operation process, the steps in the method can be expanded or combined as needed, and the exemplary preparation methods of these compounds can include (but are not limited to) the processes described below.
[0054] The compound of formula (I) of the present invention can be synthesized according to the route described in method A: the compound represented by chemical formula A1 reacts with benzaldehyde and methylhydrazine to prepare A2; A2 is cyclized to form A3 under the catalysis of Lewis acid; A3 is substituted by 3-bromocyclopentylimide to generate the target product A4,
[0055]
[0056] Wherein: R2 and R3 are as defined in the present invention.
[0057] The compound of formula (I) of the present invention can also be synthesized according to the route described in method B: first, phthalazinone B2 is obtained by condensing o-formylbenzoic acid B1 as a starting material with hydrazine hydrate under heating conditions. B2 is reacted with dimethyl 2-bromoglutarate (B 10 ) to obtain B3, and then to obtain B4 by ring contraction catalyzed by sodium amide. 10 Using glutaric acid B7 as raw material, B8, B9 and B10 were obtained by one-pot method through thionyl chloride acylation, liquid bromine substitution and methanol esterification. 10 ,
[0058]
[0059] The compound of formula (I) of the present invention can also be synthesized according to the route described in method C: the synthesis of compound A4 is the same as route A. An unsaturated nitrogen-containing non-aromatic ring compound R and methyl 4-bromomethylbenzoate undergo a substitution reaction to obtain C5. The methyl benzoate portion of C5 is first completely reduced to an alcohol (compound C6), and then incompletely oxidized to an aldehyde C7. Finally, C7 undergoes a reductive amination reaction with the aromatic amino group of the aforementioned compound A4, so that the two are connected to form an imine to obtain the target product.
[0060]
[0061] wherein R is the B ring as defined in formula (III).
[0062] The compound of formula (I) of the present invention can also be synthesized according to the route described in method D: 1-tert-butyloxycarbonylpiperazine and a halogenated aromatic ring compound R undergo a Buchwald-Hartwig carbon-nitrogen coupling reaction under the conditions of Pd2(dba)3 as a catalyst, X-Phos as a ligand, and NaOtBu as a base to generate a compound D5. The Boc protecting group on N of compound D5 is removed to obtain D6. The subsequent synthesis steps are consistent with the synthesis route C, and the compounds D7, D8, and D9 are obtained respectively through substitution with methyl 4-bromomethylbenzoate, reduction with DIBAL, and oxidation with manganese dioxide. Compound D9 undergoes a reductive amination reaction with A4 to obtain the target compound.
[0063]
[0064] For the compounds shown in formula (I) disclosed in the present invention, as well as the preparation methods, drug compositions and treatment schemes of the compounds, those skilled in the art can refer to the contents of this article and appropriately improve the process parameters to achieve them. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The products, methods, and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0065] In some embodiments of the present invention, provided are compounds of formula (I) and pharmaceutically acceptable salts, prodrugs, stable isotope derivatives, isomers, solvates, polymorphic forms and pharmaceutical compositions thereof, wherein the compounds are selected from but not limited to:
[0066]
[0067]
[0068]
[0069] In the present invention, unless otherwise indicated in the context, the words, phrases and symbols used below have the following meanings. The following abbreviations and terms have the following meanings throughout the text:
[0070] The term "alkyl" refers to a hydrocarbon group selected from saturated straight and branched chain hydrocarbon groups. Examples of alkanes include methyl, ethyl, 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"), 1-butyl or n-butyl ("n-Bu"), 2-methyl-1-propyl or isobutyl ("i-Bu"), 1-methylpropyl or sec-butyl ("s-Bu"), and 1,1-dimethylethyl or tert-butyl ("t-Bu"). Examples of other alkyl groups include 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl and 3,3-dimethyl-2-butyl groups.
[0071] Lower alkyl refers to an alkyl group having 1 to 8, preferably 1 to 6, more preferably 1 to 4 carbon atoms; lower alkenyl or alkynyl refers to an alkenyl or alkynyl group having 2 to 8, 2 to 6 or 2 to 4 carbon atoms.
[0072] The term "alkenyl" refers to a hydrocarbon group selected from straight and branched hydrocarbon groups, which includes at least one C=C double bond and 2-18 carbon atoms. Examples of alkenyl groups can be selected from vinyl (etheny1 or vinyl), prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, but-1,3-dienyl, 2-methylbut-1,3-dienyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hex-1,3-dienyl groups.
[0073] The term "alkynyl" refers to a hydrocarbon group selected from straight and branched hydrocarbon groups, which includes at least one C, C triple bond and 2-18 carbon atoms. Examples of alkynyl groups include ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl and 3-butynyl groups.
[0074] The term "cycloalkyl" refers to a hydrocarbon group selected from saturated and partially unsaturated cycloalkyl groups, including monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups, and cycloalkyl groups may have 3-12 carbon atoms. For example, cycloalkyl groups may be monocyclic groups with 3-12 carbon atoms. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl. Examples of bicyclic cycloalkyls include structures consisting of 7-12 ring atoms arranged to form a bicyclic ring selected from [4,4], [4,5], [5,5], [5,6] and [6,6] ring systems or a bridged bicyclic ring selected from bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane and bicyclo[3.2.2]nonane. The ring may be saturated or have at least one double bond (i.e., partially unsaturated), but is not fully conjugated and is not aromatic (as defined herein).
[0075] The term "aryl" herein refers to a group selected from the following: 5-membered and 6-membered carbocyclic aromatic rings, for example, phenyl: bicyclic ring systems such as 7-12 membered bicyclic ring systems, wherein at least one ring is carbocyclic and aromatic, selected from, for example, naphthalene, 1,2-dihydroindane and 1,2,3,4-tetrahydroquinoline: and tricyclic ring systems such as 10-15 membered tricyclic ring systems, wherein at least one ring is carbocyclic and aromatic, such as fluorene.
[0076] For example, aryl is selected from 5-membered and 6-membered carbocyclic aromatic rings, which are fused to 5-7-membered cycloalkyl or a heterocyclic ring optionally containing at least one heteroatom selected from N, O and S, provided that the connection point is on the carbocyclic aromatic ring when the carbocyclic aromatic ring is fused to the heterocyclic ring, and the connection point can be on the carbocyclic aromatic ring or on the cycloalkyl when the carbocyclic aromatic ring is fused to the cycloalkyl. Divalent groups formed by substituted benzene derivatives and having free valences on ring atoms are referred to as substituted phenylene groups. Divalent groups derived from monovalent polycyclic hydrocarbons whose names end with "base" by removing one hydrogen atom from carbon atoms with free valences are named by adding "subunit" to the names of the corresponding monovalent groups, such as naphthyl with two connection points is called naphthylene. However, aryl does not include heteroaryl or overlap with heteroaryl, which are defined separately below. Therefore, if one or more carbocyclic aromatic rings are fused to heterocyclic aromatic rings, the resulting ring system is a heteroaryl defined herein, rather than an aryl.
[0077] The term "halogen" refers to F, Cl, Br or I.
[0078] The term "heteroalkyl" refers to an alkyl group that includes at least one heteroatom.
[0079] The term "heteroaryl" refers to a group selected from:
[0080] 5-7 membered aromatic monocyclic ring containing 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon;
[0081] 8-12 membered bicyclic rings comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon, and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring;
[0082] An 11-14 membered tricyclic ring comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon, and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring.
[0083] For example, heteroaryl includes a 5-7 membered heterocyclic aromatic ring fused to a 5-7 membered cycloalkyl ring. For such fused bicyclic heteroaryl ring systems, where only one ring contains at least one heteroatom, the point of attachment can be on the heteroaromatic ring or the cycloalkyl ring.
[0084] When the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to each other. In some embodiments, the total number of S and O atoms in the heteroaryl group does not exceed 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle does not exceed 1.
[0085] Examples of heteroaryl groups include, but are not limited to (numbered from the preferred designated attachment position 1) pyridyl (e.g., 2-pyridyl, 3-pyridyl, or 4-pyridyl), cinnolinyl, pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 2,4-imidazolyl, imidazopyridinyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, thienyl, triazinyl, benzothienyl, furanyl, benzofuranyl, benzimidazolyl, indolyl, isoindolyl, indolinyl, phthalazinyl, pyrazinyl, pyridazinyl, pyrrolyl, triazolyl, quinolinyl, isoquinolinyl, pyrazolyl, pyrrolopyridinyl (e.g., 1H-pyrrolo[2,3-b]pyridin-5-yl), pyrazolopyridinyl (e.g., 1H-pyrazolo[3 , 4-b]pyridin-5-yl), benzoxazolyl (e.g., benzo[d]oxazol-6-yl), pteridinyl, purinyl, 1-oxa-2,3-oxadiazolyl, 1-oxa-2,4-oxadiazolyl, 1-oxa-2,5-oxadiazolyl, 1-oxa-3,4-oxadiazolyl, 1-thia-2,3-oxadiazolyl, 1-thia-2,4-oxadiazolyl, 1-thia-2,3-oxadiazolyl hetero-2,5-oxadiazolyl, 1-thia-3,4-oxadiazolyl, furazolyl, benzofurazolyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridinyl, benzothiazolyl (e.g., benzo[d]thiazol-6-yl), indazolyl (e.g., 1H-indazol-5-yl), and 5,6,7,8-tetrahydroisoquinoline.
[0086] The term "heterocyclic" or "heterocycle" or "heterocyclyl" refers to a ring selected from the following: 4-12 membered monocyclic, bicyclic and tricyclic saturated and partially unsaturated rings, which contain at least one carbon atom in addition to 1, 2, 3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen. "Heterocycle" also refers to a 5-7 membered heterocycle fused to a 5, 6 and / or 7 membered cycloalkyl, carbocyclic aromatic or heteroaromatic ring and containing at least one heteroatom selected from N, O and S, provided that when the heterocycle is fused to the carbocyclic aromatic or heteroaromatic ring, the point of attachment is on the heterocycle, and when the heterocycle is fused to a cycloalkyl, the point of attachment can be on the cycloalkyl or heterocycle.
[0087] "Heterocycle" also refers to an aliphatic spirocycle containing at least one heteroatom selected from N, O and S, provided that the point of attachment is on the heterocycle. The ring may be saturated or contain at least one double bond (i.e., partially unsaturated). The heterocycle may be substituted with oxo. The point of attachment may be a carbon atom or a heteroatom in the heterocycle. A heterocycle is not a heteroaryl as defined herein.
[0088] Examples of heterocycles include, but are not limited to (numbered from the preferred designated attachment position 1) 1-pyrrolidinyl, 2-pyrrolidinyl, 2,4-imidazolidinyl, 2,3-pyrazolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2,5-piperazinyl, pyranyl, 2-morpholinyl, 3-morpholinyl, oxiranyl, aziridinyl, thiiranyl, azetidinyl, , oxetanyl, thietanyl, 1,2-dithietanyl, 1,3-dithietanyl, dihydropyridyl, tetrahydropyridyl, thiomorpholinyl, thioxany1, piperazinyl, homopiperazinyl, homopiperidinyl, azepanyl, oxepany1, thiepany1, 1,4-oxathiany1, 1,4- dioxepanyl, 1,4-oxathiepanyl, 1,4-oxazepanyl, 1,4-dithiepanyl, 1,4-thiazepanyl and 1,4-diazepanyl 1,4-dithianyl, 1,4-azathianyl, oxazepinyl, diazepinyl, thiazepinyl, dihydrothienyl, dihydropyranyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl , indolyl, 2H-pyranyl, 4H-pyranyl, 1,4-dihexyl, 1,3-dioxolane, pyrazolinyl, pyrazolidinyl, dithioxanyl, dithiolanyl, pyrazolidinylimidazolinyl, pyrimidinyl, 1,1-dioxo-thiomorpholinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl. Substituted heterocycles also include ring systems substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl and 1,1-dioxo-1-thiomorpholinyl.
[0089] The term "fused ring" as used herein refers to a polycyclic ring system such as a bicyclic or tricyclic ring system in which two rings share only two ring atoms and one bond. Examples of fused rings may include fused bicyclic alkyl rings, such as bicyclic rings composed of 7-12 ring atoms arranged in a [4,4], [4,5], [5,5], [5,6] and [6,6] ring systems described above: fused bicyclic aryl rings, such as the 7-12 membered bicyclic aryl ring system described above, fused tricyclic aryl rings, such as the 10-15 membered tricyclic aryl ring system described above; fused bicyclic heteroaryl rings, such as the 8-12 membered bicyclic heteroaryl rings described above; fused tricyclic heteroaryl rings, such as the 11-14 membered tricyclic heteroaryl rings described above; and fused bicyclic or tricyclic heterocyclyl rings described above.
[0090] The compound may contain an asymmetric center and thus may exist as an enantiomer. When the compound has two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers fall into the broader category of stereoisomers. All these possible stereoisomers include substantially pure resolved enantiomers, racemic mixtures thereof, and diastereomeric mixtures. All stereoisomers of the compound and / or pharmaceutically acceptable salts thereof are included. Unless otherwise stated, a reference to an isomer is applicable to any possible isomer. When the isomeric component is not specifically indicated, all possible isomers are included.
[0091] When compounds contain olefinic double bonds, unless specified otherwise, it is meant to include both E and Z geometric isomers.
[0092] Some compounds may exist as tautomers. For example, a compound containing a carbonyl -CH2C(O)- group (keto form) may undergo tautomerism to form a hydroxyl -CH=C(OH)- group (enol form). The present invention also includes individual keto and enol forms as well as mixtures thereof.
[0093] The compounds shown in formula (I), (II), (III), and (IV) of the present invention can also be in the form of their salts, generally salts formed with organic or inorganic bases or acids. Physiologically acceptable salts are preferred in the present invention. The physiologically acceptable salts of the compounds of the present invention can be salts of the substances of the present invention with inorganic acids, carboxylic acids, or sulfonic acids, and particularly preferably, for example, salts formed with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, perchloric acid, fumaric acid, acetic acid, propionic acid, succinic acid, glycolic acid, formic acid, lactic acid, maleic acid, tartaric acid, citric acid, pamoic acid, malonic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, fumaric acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, hydroxynaphthoic acid, hydroiodic acid, malic acid, and tannic acid. Other acids, such as oxalic acid, although not pharmaceutically acceptable in themselves, can be used to prepare salts used as intermediates to obtain the compounds of the present invention and pharmaceutically acceptable salts thereof.
[0094] Physiologically acceptable salts may likewise be metal or ammonium salts of the compounds of the invention having free carboxyl groups. Particularly preferred are ammonium salts of sodium, potassium, magnesium or calcium salts, and inorganic ammonia or organic amines such as ethylamine, diethylamine, triethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, N-methylglucamine and procaine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylenediamine.
[0095] The compounds of the present invention may exist in tautomeric forms, and the present invention also encompasses such forms.
[0096] The compounds of the present invention may also be possible solvates thereof.
[0097] The present invention also relates to a medicine comprising at least one compound of the present invention, which preferably also comprises one or more pharmacologically acceptable excipients or carriers together, and also relates to its use for the above-mentioned purpose. The pharmaceutical carriers here include, but are not limited to, ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins such as human albumin, buffer substances such as phosphates, glycerol, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, beeswax, lanolin. The active ingredient can have systemic and / or local effects, so it can be administered by suitable routes, such as oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, transdermal, conjunctival, topical or in the form of implants.
[0098] The active ingredient can also be administered in administration forms suitable for these administration routes:
[0099] Suitable for oral administration are known administration forms which deliver the active ingredient rapidly and / or in a modified manner, such as tablets (uncoated or coated, such as tablets with enteric or mol coatings), capsules, dragees, granules, pellets, powders, emulsions, suspensions and aerosols.
[0100] With parenteral administration it is possible to avoid the absorption step (intravenous, intraarterial, intracardiac, intraspinal or intralumbar administration) or to include the absorption (intramuscular, subcutaneous, intradermal, transdermal or intraperitoneal administration). Suitable administration forms for parenteral administration are, in particular, preparations in the form of solutions, suspensions, emulsions, lyophilizates and sterile powders for injection and infusion.
[0101] Suitable for other routes of administration are, for example, drugs for inhalation (especially powder inhalation, spray), nasal drops / solutions, sprays; tablets or capsules for lingual, sublingual or buccal administration, suppositories, preparations for the ears and eyes, vaginal capsules, aqueous suspensions (lotions, shaken mixtures), lipophilic suspensions, ointments, creams, emulsions, pastes, dusting powders or implants, such as stents.
[0102] The active ingredient can be converted into the administration form by methods known per se. It can be achieved with inert, non-toxic, suitable pharmaceutical excipients. It particularly includes carriers (e.g. microcrystalline cellulose), solvents (e.g. liquid polyethylene glycol), emulsifiers (e.g. sodium lauryl sulfate), dispersants (e.g. polyvinyl pyrrolidone), synthetic and natural biopolymers (e.g. proteins), stabilizers (e.g. antioxidants and ascorbic acid), colorants (e.g. inorganic pigments such as iron oxide) or flavoring agents and / or taste masking agents. In suitable cases, the active ingredient can be present in one or more of the above-mentioned carriers in the form of microencapsulation. BRIEF DESCRIPTION OF THE DRAWINGS
[0103] Figure 1 The inhibitory effect of compounds I-4 and I-8 on human multiple myeloma RPMI-8226 xenograft tumors.
[0104] Figure 2 The inhibitory effect of compounds I-4 and I-8 on human multiple myeloma NCI-H929 xenograft tumors.
[0105] Figure 3 The inhibitory effect of compounds I-4 and I-8 combined with dexamethasone on human multiple myeloma NCI-H929 xenograft tumors. DETAILED DESCRIPTION
[0106] More detailed information on the preparation of the compounds of general formula (I) can be found in the following examples. However, the following examples are only preferred illustrative schemes of the present invention and are used to illustrate the present invention rather than to limit the scope of the present invention.
[0107] For all the following examples, standard operations and purification methods known to those skilled in the art can be used. Unless otherwise indicated, all temperatures are expressed in ° C (Celsius). The structures of the compounds are confirmed by nuclear magnetic resonance (NMR) or mass spectrometry (MS). The melting points of the compounds are determined by RY-1 type melting point apparatus, and the thermometer is uncalibrated and is given in ° C. 1 HNMR was measured by a JNM-ECA-600 nuclear magnetic resonance instrument from Japan Electronics. Mass spectra were measured by an API3000 (ESI) mass spectrometer. All reaction solvents were not subjected to standardization pretreatment unless otherwise specified. In the following examples, % refers to mass percentage unless otherwise specified. Silica gel for column chromatography was produced by Qingdao Ocean Chemical Plant (200-300 mesh); silica gel plates for thin layer chromatography were prefabricated thin layer chromatography silica gel plates produced by Yantai Institute of Chemical Industry. The compounds of the present invention can be prepared by referring to conventional methods in the art and using appropriate reagents, raw materials and purification methods known to those skilled in the art.
[0108] Example 1: Synthesis of 3-(3-methyl-6-nitro-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-11)
[0109]
[0110] [1-1] Synthesis of methyl 2-(bromomethyl)-4-nitrobenzoate (Compound <1-1>)
[0111] Weigh 10g (51.23mmol) of methyl 2-methyl-4-nitrobenzoate and dissolve it in 20mL of dichloroethane. Add 20.4mg (2.56mmol) of AIBN4 and stir to dissolve it completely. Heat to 80℃ and add 10.94g of NBS (61.48mmol) in batches. After 1h of reaction, TLC detection shows that the reaction is complete. Stop heating and gradually cool the reaction solution to 0℃. After 1h, a large amount of white crystals precipitate. Filter to remove the crystals. Concentrate the filtrate and separate it by silica gel column chromatography (eluent is V 石油醚 / V 乙酸乙酯 =100 / 1) to obtain 10.20 g of intermediate 1-1, colorless oily liquid, with a yield of 72.65%. ESI-MS m / z: 274.04 [M+H] + .
[0112] [1-2] Synthesis of methyl (E)-2-((2-benzylidene-1-methylhydrazine)methyl)-4-nitrobenzoate (Compound <1-2>)
[0113] Weigh 1.89 g (13.14 mmol) of methylhydrazine sulfate and 1.39 g (13.14 mmol) of anhydrous sodium carbonate, suspend them in 20 mL of methanol, stir, and heat to 60°C. After 1 hour, add 1.35 mL (13.14 mmol) of benzaldehyde and 3.00 g (10.95 mmol) of compound 1-1 to the reaction system, and keep stirring at 60°C for 3 hours. After TLC monitoring shows that the reaction is complete, filter to remove the solid, and concentrate the filtrate and chromatograph on a silica gel column (eluent: V 石油醚 / V 乙酸乙酯 =15 / 1) to obtain 2.21 g of compound 1-2 as an orange-yellow solid with a yield of 61.73%. ESI-MS m / z: 328.12 [M+H] + .
[0114] [1-3] Synthesis of 3-methyl-6-nitro-3,4-dihydrophthalazin-1(2H)-one (Compound <1-3>)
[0115] Weigh 1.17 g of compound 1-2 (3.57 mmol) and add 5 mL of V 正丁醇 / V 冰醋酸 = 1 / 1 mixed solvent, stirred until completely dissolved, added anhydrous zinc chloride 24.4 mg (0.18 mmol), heated to 120 ° C for 6 hours. Stop heating and stirring, let stand overnight, a yellow solid precipitated, filtered, washed with petroleum ether and dried to obtain compound 1-3 (590 mg, yield 79.84%). ESI-HRMS m / z: 206.0560 [MH] - .
[0116] [1-4] Synthesis of 3-(3-methyl-6-nitro-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-11)
[0117] Weigh 500 mg of compound 1-3 (2.42 mmol) and dissolve it in 10 mL of anhydrous tetrahydrofuran, protect with nitrogen, stir in an ice bath and add 3.6 mL of LiHMDs (3.60 mmol, 1N in THF), stir in an ice bath for 30 min after the addition is complete, then add 695 mg (3.62 mmol) of 3-bromopiperidine-2,6-dione dissolved in 5 mL of anhydrous tetrahydrofuran, and naturally warm to room temperature for 3 h. After TLC detection shows that the reaction no longer proceeds, add saturated ammonium chloride solution to the reaction system to quench the reaction, separate the liquids, extract the aqueous phase with ethyl acetate (3 x 10 mL), combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate the filtrate and purify it with silica gel column chromatography (eluent is V 二氯甲烷 / V 甲醇=50 / 1) to obtain 20 mg of compound I-11 as a white slightly yellow solid with a yield of 2.60%. ESI-MS m / z: 319.10 [M+H] + . 1 H-NMR (600MHz, DMSO-d6) δppm: 10.99 (s, 1H), 8.35 (dd, J = 8.3, 1.3Hz, 1H), 8.26 (d d,J=7.7,1.3Hz,1H),7.74(t,J=7.9Hz,1H),5.19(dd,J=12.4,4.9Hz,1H),4.68(d ,J=17.2Hz,1H),4.50(d,J=17.1Hz,1H),2.86(ddd,J=17.1,13.7,5.3Hz,1H),2.5 8(d,J=17.2Hz,1H),2.51(s,3H),2.43(dd,J=13.2,4.4Hz,1H),2.14-2.10(m,1H).
[0118] Example 2: Synthesis of 3-(6-amino-3-methyl-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-10)
[0119]
[0120] [2-1] Weigh 20 mg (0.06 mmol) of compound I-11 and add it to 5 mL of methanol. Stir until part of the solid dissolves. Add about 8.05 mg (0.13 mmol) of activated zinc powder, add 300 μL of 3M HCl (aq.) dropwise while stirring, and react overnight at room temperature. The next day, the solid completely dissolved, and TLC detection showed that the reaction was complete. Filter to remove the zinc powder, concentrate the filtrate, and separate by preparative TLC to obtain 13 mg of compound I-10 as a white solid with a yield of 71.78%. ESI-MS m / z: 289.13 [M+H] + . 1H-NMR (600MHz, DMSO-d6) δ10.85(s,1H),7.51(d,J=8.4Hz,1H),6.53(dd,J=8.4,2. 2Hz,1H),6.35(d,J=2.2Hz,1H),5.93(s,2H),5.09(dd,J=12.5,5.2Hz,1H),4.25(s ,1H),3.82(d,J=12.2Hz,1H),2.82(ddd,J=17.1,13.7,5.3Hz,1H),2.58–2.53(m,1 H), 2.50 (s, 3H), 2.39 (qd, J = 13.0, 4.3Hz, 1H), 2.02 (dtd, J = 12.8, 5.2, 2.7Hz, 1H).
[0121] Example 3: Synthesis of 3-(3-methyl-5-nitro-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-9)
[0122]
[0123] [3-1] Synthesis of methyl (E)-2-((2-benzylidene-1-methylhydrazine)methyl)-3-nitrobenzoate (Compound <3-1>)
[0124] Weigh 10.50 g (72.84 mmol) of methylhydrazine sulfate and 11.60 g (109.26 mmol) of anhydrous sodium carbonate, suspend in 200 mL of methanol, stir, and heat to 60°C. After 1 hour, add 7.29 mL (72.84 mmol) of benzaldehyde and 20.00 g (72.84 mmol) of methyl 2-bromomethyl-3-nitrobenzoate to the reaction system, and keep stirring at 60°C for 3 hours. After TLC monitoring, filter out the solid after the complete reaction of methyl 2-bromomethyl-3-nitrobenzoate, concentrate the filtrate and chromatograph on a silica gel column (eluent: V 石油醚 / V 乙酸乙酯 =15 / 1) to obtain 17.0 g of compound 3-1 as an orange-yellow solid with a yield of 71.1%. ESI-MS m / z: 328.12 [M+H] + .
[0125] [3-2] Synthesis of 3-methyl-5-nitro-3,4-dihydrophthalazin-1(2H)-one (Compound <3-2>)
[0126] Weigh 17.0 g of compound 3-1 (52.00 mmol), add 50 mL of V 正丁醇 / V 冰醋酸= 1 / 1 mixed solvent, stirred until completely dissolved, added anhydrous zinc chloride 354mg (2.60mmol), heated to 120℃ for 6h. Stop heating and stirring, let stand overnight, yellow solid precipitated, filtered, washed with petroleum ether and dried to obtain compound 3-2 (5.90g, yield 54.8%). ESI-HRMS m / z: 206.0560[M+H] + .
[0127] [3-3] Synthesis of 3-(3-methyl-5-nitro-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-9)
[0128] Weigh 5.00g of compound 3-2 (24.14mmol) and dissolve it in 50mL of anhydrous tetrahydrofuran, protect with nitrogen, stir in an ice bath and add 36mL of LiHMDs (36.00mmol, 1N in THF), stir in an ice bath for 30min after the addition is complete, then add 6.95g (36.22mmol) of 3-bromopiperidine-2,6-dione dissolved in 20mL of anhydrous tetrahydrofuran, and naturally warm to room temperature for 3h. After TLC detection shows that the reaction no longer continues, add saturated ammonium chloride solution to the reaction system to quench the reaction, separate the liquids, extract the aqueous phase with ethyl acetate (3x 10mL), combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate the filtrate and purify it by silica gel column chromatography (eluent is V 二氯甲烷 / V 甲醇 =50 / 1) to obtain 4.01 g of compound I-9 as a white slightly yellow solid with a yield of 52.10%. ESI-HRMS m / z: 318.3001 [M] + . 1 H-NMR (600MHz, DMSO-d6) δppm: 11.00 (s, 1H), 8.36 (dd, J=8.2, 1.3Hz, 1H), 8.26 (dd, J=7.7, 1.3Hz,1H),7.74(t,J=8.0Hz,1H),5.20(dd,J=12.8,5.1Hz,1H),4.68(d,J=17.2Hz,1H),4. 51(d,J=18.5Hz,1H),2.86(ddd,J=17.2,13.8,5.4Hz,1H),2.60(t,J=4.0Hz,1H),2.57(d,J =3.7Hz,2H),2.45(d,J=10.2Hz,1H),2.43-2.38(m,1H),2.12(ddq,J=10.5,5.3,2.6Hz,1H).
[0129] Example 4: Synthesis of 3-(5-amino-3-methyl-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-4)
[0130]
[0131] [4-1] Weigh 4.00 g (12.58 mmol) of compound I-9 and add it to 40 mL of methanol. Stir until part of the solid dissolves. Add about 133.86 mg (1.26 mmol) of 5% Pd-C, replace with hydrogen, and then connect a balloon filled with hydrogen. Let the reaction proceed overnight at room temperature. The next day, the solid completely dissolved. TLC detection showed that the reaction was complete. Celite was filtered to remove and recover the wet palladium-carbon catalyst. The filtrate was concentrated and purified by silica gel column chromatography (the eluent was V 二氯甲烷 / V 甲醇 =50 / 1-10 / 1) to obtain product I-4 1.21g, white solid, yield 33.34%. ESI-HRMS m / z: 289.1269 [M+H] + ; 1 H-NMR (600MHz, DMSO-d6) δppm: 10.90 (s, 1H), 7.13-7.06 (m, 2H), 6.86 (dd, J= 7.6,1.5Hz,1H),5.19(s,2H),5.11(dd,J=12.7,5.1Hz,1H),4.18(d,J=16.2Hz ,1H),3.97(d,J=16.2Hz,1H),2.83(ddd,J=17.1,13.8,5.3Hz,1H),2.58-2.5 3(m,1H),2.47(s,3H),2.45-2.37(m,1H),2.05(dtd,J=12.8,5.2,2.6Hz,1H).
[0132] Example 5: Synthesis of 3-(3-methyl-5-(methylamino)-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-2)
[0133]
[0134] [5-1] Weigh 300 mg (1.04 mmol) of compound I-4 and paraformaldehyde (100 mg, 1.61 mmol) into a 25 mL single-necked flask, and add 10 mL of water. Place the reaction flask on a stirring table and add formic acid (0.32 g, 7 mmol) while stirring. Then heat to 70 °C for 6 hours, and monitor the completion of the reaction by TLC. Cool the reaction flask to room temperature, filter, and wash the solid with 10 mL of water, 10 mL of dichloromethane, and 10 mL of tetrahydrofuran, respectively. Dry under vacuum, and purify the crude product by silica gel column chromatography (eluent: V 二氯甲烷 / V 甲醇 =50 / 1-10 / 1) to obtain compound I-2, 180 mg, yield 57.32%, white solid. ESI-HRMS m / z: 303.1455 [M+H] + ; 1 H-NMR (600MHz, DMSO-d6) δppm: 10.90 (s, 1H), 7.25 (t, J = 7.9Hz, 1H), 7.12 (dd, J = 7.6, 1.1Hz, 1H) ,6.76(dd,J=8.2,1.1Hz,1H),5.42(d,J=5.0Hz,1H),5.11(dd,J=12.7,5.1Hz,1H),4.19(d,J=16 .2Hz,1H),3.98(d,J=16.2Hz,1H),2.83(ddd,J=17.1,13.8,5.3Hz,1H),2.73(d,J=4.8Hz,3H),2 .60-2.54(m,1H),2.46(s,3H),2.42(dd,J=13.3,4.4Hz,1H),2.06(dtd,J=12.8,5.2,2.6Hz,1H).
[0135] Example 6: Synthesis of 3-(1-oxophthalazine-2(1H)-yl)piperidine-2,6-dione (Compound YJ-1a)
[0136]
[0137] [6-1] Synthesis of dimethyl 2-bromoglutarate (Compound <6-1>)
[0138] Weigh glutaric acid (2.64g, 20mmol) and place it in a 50mL two-necked round-bottom flask, add 30mL of dichloromethane, place the reaction flask on a stirring table at room temperature and stir until the suspension is reached, then slowly add thionyl chloride (7.13g, 60mmol) and heat to reflux. After reacting for 10 hours, let the reaction flask stand and cool to room temperature, spin dry the solvent and unreacted thionyl chloride to obtain a golden liquid. Transfer the golden liquid to a 100mL three-necked round-bottom flask, insert a thermometer and a serpentine condenser. Heat to 80°C, and add liquid bromine (3.20g, 20.05mmol) to the reaction solution through a dropping funnel. After the first drop of bromine is dripped, the reaction solution turns red, and the second drop of bromine is added after the red color fades. After the bromine is dripped in 6 hours, continue to maintain 80°C for 12 hours. After the reaction is completed, the reaction bottle is left to stand and cool to room temperature, 50 mL of methanol is added to a 100 mL single-necked flask and placed in an ice bath and stirred for 10 minutes, and the reaction solution is slowly added dropwise to the methanol. After the dropwise addition, the reaction bottle is placed at room temperature and stirred for 3 hours. After the solvent is dried by rotary evaporator, 5.22 g of red liquid is obtained. The red liquid is washed 3 times with 20 mL of saturated sodium bicarbonate solution and 20 mL of saturated sodium thiosulfate solution, and then washed once with 30 mL of saturated brine. The washed red liquid is collected by vacuum distillation at 80-85 ° C to obtain 6-1, 3.63 g, with a yield of 76.1%, and a light yellow liquid. 1 H-NMR (600MHz, CDCl3) δppm: 4.39 (dd, J = 8.5, 5.8Hz, 1H), 3.79 (s, 3H), 3.70 (s, 3H), 2.59-2.46 (m, 2H), 2.44-2.34 (m, 2H). ESI-MS m / z: 240.99 [M+H] + .
[0139] [6-2] Synthesis of o-phthalazinon-1-(2H)-one (Compound <6-2>)
[0140] Weigh o-formylbenzoic acid (7.50 g, 50 mmol) and place it in a 200 mL single-mouth round-bottom flask, add 50 mL of n-butanol, place the reaction flask on a stirring table at room temperature and stir until a suspension, then slowly add 85% hydrazine hydrate (3.53 g, 60 mmol). Heat to 100 ° C, react for two hours and then let the reaction solution stand to room temperature. Filter, wash the solid with dichloromethane first, then wash with water, and dry to obtain 6-2 5.85 g, yield 80.5%, white needle-shaped crystals. 1H-NMR (600MHz, DMSO-d6) δppm: 12.66 (s, 1H), 8.37 (d, J = 0.7Hz, 1H), 8.24 (dq, J = 7.8, 0.9Hz, 1H), 7.97-7.91 (m, 2H), 7.86 (dp, J = 8.5, 4.3Hz, 1H); ESI-MS m / z:147.06[M+H] + .
[0141] [6-3] Synthesis of dimethyl 2-(1-oxophthalazine-2(1H))glutarate (Compound <6-3>)
[0142] Weigh 6-2 (0.44 g, 3 mmol) and potassium carbonate (0.46 g, 3.3 mmol) into two 50 mL round-bottom flasks, add 10 mL DMF and place the reaction flask on a stirring table. Add 6-1 (0.87 g, 3.6 mmol) under rapid stirring, and then raise the reaction temperature to 80 ° C. After 18 hours of reaction, the reaction is completed by monitoring by TLC. After the reaction flask is allowed to stand at room temperature, the reaction solution is dripped into 20 mL of cold water, extracted three times with 30 mL of ethyl acetate, and the organic layers are combined and dried over anhydrous sodium sulfate. Then add silica gel and mix well, and pass through column chromatography (eluent is V 石油醚 / V 乙酸乙酯 =15 / 1), to obtain 6-3, 0.78 g, yield 86.2%, colorless transparent liquid. 1 H-NMR (400MHz, CDCl3) δppm: 8.43 (dd, J=7.8, 1.4Hz, 1H), 8.22 (s, 1H), 7.89-7.76 (m, 2H), 7.73 (dd, J=7.9, 1.3 Hz,1H),5.74(dd,J=10.0,5.0Hz,1H),3.74(s,3H),3.63(s,3H),2.71-2.47(m,2H),2.43-2.31(m,2H).ESI-MS m / z:305.11[M+H] + .
[0143] [6-4] Synthesis of 3-(1-oxophthalazine-2(1H))piperidine-2,6-dione (Compound YJ-1a)
[0144] Weigh sodium amide (0.12 g, 3 mmol) and place it in a 50 mL two-necked round-bottom flask. Protect the nitrogen with a three-way valve, then add 10 mL of ultra-dry tetrahydrofuran through a syringe, and then place the reaction bottle in a -30 ° C cooling bath. After cooling for 20 minutes, 6-3 (0.60 g, 2 mmol) was dissolved in 10 mL of ultra-dry tetrahydrofuran and slowly dripped into the reaction bottle through a syringe within 10 minutes. After keeping the cooling bath for 6 hours, 5 mL of saturated ammonium chloride solution was slowly added, and then the reaction bottle was placed at room temperature and stirred for 30 minutes. Filter, wash the solid with 40 mL of water, 30 mL of dichloromethane, and 30 mL of tetrahydrofuran, respectively, and dry to obtain compound YJ-1a, 0.28 g, yield 56.5%, white solid. 1 H-NMR (400MHz, DMSO-d6) δppm: 11.07 (s, 1H), 8.52-8.48 (m, 1H), 8.28 (dt, J = 7.9, 1.0Hz, 1H), 7.99 (dd, J = 3.7, 1.1Hz, 2H), 7.91 (ddd, J =8.3,4.9,3.6Hz,1H),5.83(dd,J=12.3,5.4Hz,1H),2.94(ddd,J=17.3,13.7,5.4Hz,1H),2.67-2.52(m,2H),2.19-2.08(m,1H).ESI-MS m / z:258.09[M+H] + .
[0145] Example 7: Synthesis of 3-(1-oxo-3,4-dihydrophthalazine-2(1H))piperidine-2,6-dione (Compound YJ-2a)
[0146]
[0147] [7-1] Weigh compound YJ-1a (0.39 g, 1.5 mmol) and zinc powder (0.16 g, 2.5 mmol) into a 50 mL single-mouth round-bottom flask, add 10 mL of water, and place the reaction flask in an ice bath. After 10 minutes, slowly add 2 mL of 3 mol / L hydrochloric acid to the reaction flask through a dropping funnel, and drip it all over in 10 minutes. Keep the reaction in an ice bath for 3 hours, then warm it to room temperature and stir for 30 minutes. Filter, wash the solid with water, and vacuum dry it. Then, place the resulting solid in V 二氯甲烷 / V 甲醇 = 10 / 1 20mL mixed solvent slurry, after 30 minutes of suction filtration, the filtrate was spin-dried to obtain compound YJ-2a, 0.14g, yield 37.6%, white solid. 1H-NMR (400MHz, DMSO-d6) δppm: 10.93 (s, 1H), 7.89 (dd, J = 7.7, 1.4Hz, 1H), 7.53 (td, J =7.5,1.4Hz,1H),7.42(td,J=7.6,1.3Hz,1H),7.31-7.25(m,1H),5.84(t,J=8.2Hz,1 H),5.36(dd,J=12.4,5.3Hz,1H),4.13-3.92(m,2H),2.85(ddd,J=17.2,13.8,5.4Hz, 1H),2.62-2.52(m,1H),2.38-2.23(m,1H),1.93(dtd,J=13.1,5.4,2.6Hz,1H).ESI-MS m / z:260.11[M+H] + .
[0148] Example 8: Synthesis of 3-(3-methyl-1-oxo-3,4-dihydrophthalazine-2(1H)piperidine-2,6-dione (Compound YJ-3a)
[0149]
[0150] [8-1] Weigh compound YJ-2a (0.30 g, 1 mmol) and paraformaldehyde (0.05 g, 1.5 mmol) into a 25 mL single-necked flask, and add 10 mL of water. Place the reaction flask on a stirring table and add formic acid (0.32 g, 7 mmol) while stirring. Then heat to 70 °C for 6 hours, and monitor the completion of the reaction by TLC. Cool the reaction flask to room temperature, filter, and wash the solid with 10 mL of water, 10 mL of dichloromethane, and 10 mL of tetrahydrofuran. Dry under vacuum to obtain compound YJ-3a, 0.25 g, with a yield of 93.3%, as a white solid. 1 H-NMR (400MHz, DMSO-d6) δppm: 10.96 (s, 1H), 7.77 (td, J=5.5, 2.6Hz, 1H), 7.57 (td, J=7.6, 1.8Hz, 1H), 7.43 (t ,J=7.6Hz,2H),4.96(s,2H),4.63-4.18(m,3H),3.60(s,2H),2.78(t,J=15.7Hz,1H),2.26-1.32(m,2H).ESI-MS m / z:272.10[M+H] + .
[0151] Example 9: Synthesis of 3-(1-oxophthalazine-2(1H))pyrrolidine-2,5-dione (Compound YJ-1b)
[0152]
[0153] [9-1] Synthesis of dimethyl 2-bromosuccinate (Compound <9-1>)
[0154] Weigh 2-bromosuccinic acid (1.97 g, 10 mmol) and place it in a 50 mL single-mouth round-bottom flask, add 20 mL of methanol and stir to dissolve it completely. Place the reaction bottle on a stirring table, add 3 drops of concentrated sulfuric acid while stirring at room temperature, and then raise the reaction temperature to reflux. After reflux reaction for 16 hours, cool the reaction bottle to room temperature and spin dry the solvent on a rotary evaporator. Add 30 mL of ethyl acetate to the liquid obtained by spin drying, transfer to a separatory funnel, wash 3 times with 30 mL of saturated sodium bicarbonate, and then wash once with saturated brine. The organic layer is dried with anhydrous sodium sulfate and then spin dried on a rotary evaporator to obtain 9-1, 2.05 g, with a yield of 91.2%, a colorless and transparent liquid. 1 H-NMR (600MHz, CDCl3) δppm: 4.59 (dd, J=8.8, 6.2Hz, 1H), 3.81 (s, 3H), 3.72 (s, 3H), 3.32-2.97 (m, 2H). ESI-MS m / z: 226.98 [M+H] + .
[0155] [9-2] Synthesis of o-phthalazin-1-(2H)-one (Compound <9-2>)
[0156] Weigh o-formylbenzoic acid (7.50 g, 50 mmol) into a 200 mL single-mouth round-bottom flask, add 50 mL of n-butanol, place the reaction flask on a stirring table at room temperature and stir until a suspension, then slowly add 85% hydrazine hydrate (3.53 g, 60 mmol). Heat to 100 ° C, react for two hours, and then let the reaction solution stand to room temperature. Filter, wash the solid with dichloromethane first, then wash with water, and dry to obtain 9-2 5.85 g, yield 80.5%, white needle-shaped crystals. 1 H-NMR (600MHz, DMSO-d6) δppm: 12.66 (s, 1H), 8.37 (d, J = 0.7Hz, 1H), 8.24 (dq, J = 7.8, 0.9Hz, 1H), 7.97-7.91 (m, 2H), 7.86 (dp, J = 8.5, 4.3Hz, 1H); ESI-MS m / z:147.06[M+H] + .
[0157] [9-3] Synthesis of dimethyl 2-(1-oxophthalazin-2(1H)-yl)succinate (Compound <9-3>)
[0158] Weigh 9-2 (0.44 g, 3 mmol) and potassium carbonate (0.46 g, 3.3 mmol) into two 50 mL round-bottom flasks, add 10 mL of DMF and place the reaction flask on a stirring table. Add 9-1 (0.81 g, 3.6 mmol) under rapid stirring, and then raise the reaction temperature to 80 ° C. After reacting for 24 hours, the reaction is completed by monitoring by TLC. After the reaction flask is allowed to stand at room temperature, the reaction solution is dripped into 20 mL of cold water, extracted three times with 30 mL of ethyl acetate, and the organic layers are combined and dried over anhydrous sodium sulfate. Then add silica gel and mix well, and pass through column chromatography (eluent is V 石油醚 / V 乙酸乙酯 =15 / 1), to obtain 0.77 g of 9-3, with a yield of 88%, as a colorless transparent liquid. 1 H-NMR (400MHz, CDCl3) δppm: 8.44 (dd, J=7.7, 1.5Hz, 1H), 8.19 (s, 1H), 7.88-7.69 (m, 3H), 6.08 (dd,J=8.1,6.0Hz,1H),3.75(s,3H),3.69(s,3H),3.45-3.08(m,2H).ESI-MSm / z:291.18[M+H] + .
[0159] [9-4] Synthesis of 3-(1-oxophthalazine-2(1H))pyrrolidine-2,5-dione (Compound YJ-1b)
[0160] Weigh sodium amide (0.12 g, 3 mmol) and place it in a 50 mL two-necked round-bottom flask, protect with nitrogen, add 10 mL of ultra-dry tetrahydrofuran, and then place the reaction bottle in a -30 ° C cooling bath. After cooling for 20 minutes, 9-3 (0.58 g, 2 mmol) was dissolved in 10 mL of ultra-dry tetrahydrofuran and slowly dripped into the reaction bottle through a syringe within 10 minutes. After keeping the cooling bath for 6 hours, 5 mL of saturated ammonium chloride solution was slowly added, and then the reaction bottle was stirred at room temperature for 30 minutes. Filter, wash the solid with water, dichloromethane, and tetrahydrofuran in turn, and obtain compound YJ-1b, 0.24 g, yield 50.2%, white solid. 1 H-NMR (400MHz, DMSO-d6) δppm: 11.57 (s, 1H), 8.52 (s, 1H), 8.26 (dd, J = 8.0, 1.0Hz, 1H), 8.03-7.96 (m, 2H), 7 .92(dq,J=8.3,4.3Hz,1H),5.78(s,1H),3.12(dd,J=17.8,9.5Hz,1H),2.90(dd,J=17.8,5.2Hz,1H).ESI-MS m / z:244.08[M+H] + .
[0161] Example 10: Synthesis of 3-(1-oxo-3,4-dihydrophthalazine-2(1H))pyrrolidine-2,5-dione (Compound YJ-2b)
[0162]
[0163] [10-1] Weigh compound YJ-1b (0.36 g, 1.5 mmol) and zinc powder (0.16 g, 2.5 mmol) into a 50 mL single-mouth round-bottom flask, add 10 mL of water, and place the reaction flask in an ice bath. After 10 minutes, slowly add 3 mL of 3 mol / L hydrochloric acid to the reaction flask through a dropping funnel, and drip it all over in 10 minutes. Keep the reaction in an ice bath for 3 hours, then heat it to room temperature and stir for 30 minutes. Filter, wash the solid with water, and dry it in vacuum. Then, place the obtained solid in V 二氯甲烷 / V 甲醇 = 10 / 1 20mL mixed solvent slurry, after 30 minutes of suction filtration, the filtrate was spin-dried to obtain compound YJ-2b, 0.19g, yield 35.1%, white solid. 1 H-NMR (400MHz, DMSO-d6) δppm: 11.42(s,1H),7.87(dd,J=7.8,1.3Hz,1H),7.54(td,J=7.5,1.4Hz,1H),7.42(t,J=7.5Hz,1H),7.28(d,J=7.5Hz,1H ),6.12(dd,J=9.4,7.1Hz,1H),5.49(dd,J=9.3,5.1Hz,1H),4.12-3.94(m,2H),2.94(dd,J=17.8,9.2Hz,1H),2.71(dd,J=17.8,5.1Hz,1H).ESI-MS m / z:246.09[M+H] + .
[0164] Example 11: Synthesis of 3-(7-fluoro-3-methyl-5-nitro-1-oxo-3,4-dihydrophthalazin-2(1H)yl)piperidine-2,6-dione (Compound I-13)
[0165]
[0166] [11-1] Synthesis of methyl (E)-2-((2-benzylidene-1-methylhydrazine)methyl)-5-fluoro-3-nitrobenzoate (Compound <11-1>)
[0167] Weigh 217.7 mg (2.05 mmol) of sodium carbonate and 295.5 mg (2.05 mmol) of methylhydrazine sulfate, suspend them in 10 mL of methanol, heat to 60 ° C and react for 1 h. Add 209 μL (2.05 mmol) of benzaldehyde and 500 mg of methyl 2-(bromomethyl)-5-fluoro-3-nitrobenzoate, and continue to react for 5 h. After TLC detection shows that the reaction is complete, filter out the solid, and purify the residue by silica gel column chromatography to obtain 460 mg of 11-1 as an orange-yellow solid with a yield of 77.80%. ESI-MS m / z: 346.09 [M+H] +
[0168] [11-2] Synthesis of 7-fluoro-3-methyl-5-nitro-3,4-dihydrophthalazin-1(2H)-one (Compound <11-2>)
[0169] Weigh 460 mg (1.33 mmol) of 11-1 and dissolve it in a mixed solvent consisting of 3 mL of n-butanol and 3 mL of glacial acetic acid, add 10 mg (0.07 mmol) of anhydrous zinc chloride, and heat to 120°C for 3 h. TLC detection shows that the reaction is complete, and the solution is cooled to room temperature and purified by silica gel column chromatography to obtain 11-2, 210 mg, yellow solid, with a yield of 70.12%. ESI-MS m / z: 224.05 [MH] -
[0170] [11-3] Synthesis of 3-(7-fluoro-3-methyl-5-nitro-1-oxo-3,4-dihydrophthalazin-2(1H)yl)piperidine-2,6-dione (Compound I-13)
[0171] Weigh 210 mg of 11-2 and dissolve it in 5 mL of anhydrous tetrahydrofuran, protect with nitrogen, precool at -20 ° C, add 1.2 mL of LiHMDS (1.2 mmol, 1 M in THF) to the reaction system, maintain -20 ° C and stir for 30 min, then add 358.1 mg (1.87 mmol) of 3-bromopiperidine-2,6-dione dissolved in 5 mL of anhydrous tetrahydrofuran, move to room temperature and react overnight. After TLC detection, the reaction is complete, quench with water, separate the liquid, extract the aqueous phase with ethyl acetate (2×10 mL), combine the organic phases, dry, filter, concentrate the filtrate and purify it with silica gel column chromatography to obtain compound I-13, 70 mg, white solid, yield 22.39%. 1H-NMR(600MHz,DMSO-d6)δppm:11.01(s,1H),8.31(dd,J=8.5,2.8Hz,1H),8.06(dd,J=8.0,2.8Hz,1H),5.19(dd,J=12.8,5.0Hz,1H),4.64(d,J=17 .1Hz,1H),4.49(d,J=17.1Hz,1H),2.86(ddd,J=17.0,13.7,5.4Hz,1H),2 .58(dt,J=18.4,4.7Hz,2H),2.46–2.37(m,1H),2.15–2.09(m,1H); ESI-MS m / z:337.10[M+H] + .
[0172] Example 12: Synthesis of 3-(5-amino-7-fluoro-3-methyl-1-oxo-3,4-dihydrophthalazine-2(1H)yl)piperidine-2,6-dione (Compound I-12)
[0173]
[0174] [12-1] Weigh 50 mg (0.15 mmol) of compound I-13 into a round-bottom flask, add 20 mg (0.30 mmol) of activated zinc powder and 5 mL of methanol, and then slowly drop 2 mL of 3M hydrochloric acid solution into the reaction solution. After the addition is complete, continue stirring for 1 hour. TLC detection shows that the reaction is complete, and the excess zinc powder is removed by filtration. The filtrate is concentrated and purified by silica gel column chromatography to obtain 20 mg of compound I-12 as a white solid with a yield of 43.57%. 1 H-NMR(600MHz,DMSO-d6)δppm:10.91(s,1H),6.74(dd,J=8.8,2.6Hz,1H),6.63(dd,J=11.5,2.6Hz,1H),5.56(s,2H),5.10(dd,J=12.9,5.1Hz,1H),4.14( d,J=16.1Hz,1H),3.95(d,J=16.2Hz,1H),2.87-2.79(m,1H),2.57(t,J=3.7H z,1H),2.47(s,3H),2.41(qd,J=13.0,4.2Hz,1H),2.10-2.01(m,1H); ESI-MS m / z:307.12[M+H] +
[0175] Example 13: Synthesis of tert-butyl 4-(4-(((2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxo-1,2,3,4-tetrahydrophthalazin-5-yl)amino)methyl)benzyl)piperazine-1-carboxylate (Compound I-5)
[0176]
[0177] [13-1] Synthesis of methyl (E)-2-((2-benzylidene-1-methylhydrazine)methyl)-3-nitrobenzoate (Compound <13-1>)
[0178] Weigh 10.50 g (72.84 mmol) of methylhydrazine sulfate and 11.60 g (109.26 mmol) of anhydrous sodium carbonate, suspend in 200 mL of methanol, stir, and heat to 60°C. After 1 hour, add 7.29 mL (72.84 mmol) of benzaldehyde and 20.00 g (72.84 mmol) of methyl 2-bromomethyl-3-nitrobenzoate to the reaction system, and keep stirring at 60°C for 3 hours. After TLC monitoring, filter out the solid after the complete reaction of methyl 2-bromomethyl-3-nitrobenzoate, concentrate the filtrate and chromatograph on a silica gel column (eluent: V 石油醚 / V 乙酸乙酯 =15 / 1) to obtain 17.0 g of compound 13-1 as an orange-yellow solid with a yield of 71.1%. ESI-MS m / z: 328.12 [M+H] + .
[0179] [13-2] Synthesis of 3-methyl-5-nitro-3,4-dihydrophthalazin-1(2H)-one (Compound <13-2>)
[0180] Weigh 17.0 g of compound 13-1 (52.00 mmol), add 50 mL of V 正丁醇 / V 冰醋酸 = 1 / 1 mixed solvent, stirred until completely dissolved, added anhydrous zinc chloride 354mg (2.60mmol), heated to 120℃ for 6h. Stop heating and stirring, let stand overnight, yellow solid precipitated, filtered, washed with petroleum ether and dried to obtain compound 13-2 (5.90g, yield 54.8%). ESI-HRMS m / z: 206.0560[M+H] + .
[0181] [13-3] Synthesis of 3-(3-methyl-5-nitro-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound <13-3>)
[0182] 5.00 g of compound 13-2 (24.14 mmol) was weighed and dissolved in 50 mL of anhydrous tetrahydrofuran, and nitrogen was protected. The mixture was stirred in an ice bath and 36 mL of LiHMDs (36.00 mmol, 1N in THF) was added. After the addition was completed, the mixture was stirred in an ice bath for 30 min, and then 6.95 g (36.22 mmol) of 3-bromopiperidine-2,6-dione dissolved in 20 mL of anhydrous tetrahydrofuran was added. The mixture was naturally heated to room temperature and reacted for 3 h. After TLC detection showed that the reaction did not proceed, a saturated ammonium chloride solution was added to the reaction system to quench the reaction, and the liquids were separated. The aqueous phase was extracted with ethyl acetate (3×10 mL), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (the eluent was V 二氯甲烷 / V 甲醇 =50 / 1) to obtain 4.01 g of compound 13-3 as a white slightly yellow solid with a yield of 52.10%. ESI-HRMS m / z: 318.3001 [M] + . 1 H-NMR (600MHz, DMSO-d6) δppm: 11.00 (s, 1H), 8.36 (dd, J=8.2, 1.3Hz, 1H), 8.26 (dd, J=7.7, 1.3Hz,1H),7.74(t,J=8.0Hz,1H),5.20(dd,J=12.8,5.1Hz,1H),4.68(d,J=17.2Hz,1H),4. 51(d,J=18.5Hz,1H),2.86(ddd,J=17.2,13.8,5.4Hz,1H),2.60(t,J=4.0Hz,1H),2.57(d,J =3.7Hz,2H),2.45(d,J=10.2Hz,1H),2.43-2.38(m,1H),2.12(ddq,J=10.5,5.3,2.6Hz,1H).
[0183] [13-4] Synthesis of 3-(5-amino-3-methyl-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound <13-4>)
[0184] Weigh 4.00 g (12.58 mmol) of compound 13-3 and add it to 40 mL of methanol. Stir until part of the solid dissolves. Add about 133.86 mg (1.26 mmol) of 5% Pd-C, replace with hydrogen, and then connect a balloon filled with hydrogen. Let the reaction proceed overnight at room temperature. The next day, the solid completely dissolved. TLC detection showed that the reaction was complete. Filter the diatomaceous earth to remove and recover the wet palladium-carbon catalyst. The filtrate was concentrated and purified by silica gel column chromatography (the eluent was V 二氯甲烷 / V 甲醇=50 / 1-10 / 1) to obtain compound 13-4, 1.21 g, white solid, yield 33.34%. ESI-HRMS m / z: 289.1269 [M+H] + ; 1 H-NMR (600MHz, DMSO-d6) δppm: 10.90 (s, 1H), 7.13-7.06 (m, 2H), 6.86 (dd, J= 7.6,1.5Hz,1H),5.19(s,2H),5.11(dd,J=12.7,5.1Hz,1H),4.18(d,J=16.2Hz ,1H),3.97(d,J=16.2Hz,1H),2.83(ddd,J=17.1,13.8,5.3Hz,1H),2.58-2.5 3(m,1H),2.47(s,3H),2.45-2.37(m,1H),2.05(dtd,J=12.8,5.2,2.6Hz,1H).
[0185] [13-5] Synthesis of tert-butyl 4-(4-(methoxycarbonyl)benzyl)piperazine-1-carboxylate (Compound <13-5>)
[0186] Weigh 1.00 g (4.37 mmol) of methyl 4-bromomethylbenzoate and dissolve it in 20 mL of ethyl acetate. Add 1.21 g (8.74 mmol) of potassium carbonate and 0.81 g (4.37 mmol) of 1-tert-butyloxycarbonylpiperazine. Heat to 60 °C and react for 1 h. TLC detection shows that the reaction is complete and a large amount of white solid is generated. The solid is removed by filtration and the filtrate is concentrated to obtain a colorless oily liquid, which is compound 13-5, which can be directly used in the next step without purification. ESI-HRMS m / z: 335.1965 [M+H] + ; 1 H-NMR(600MHz,DMSO-d6)δppm:7.97-7.91(m,2H),7.50-7.43(m,2H),3.86( s,3H),3.55(s,2H),3.37-3.29(m,4H),2.32(t,J=5.1Hz,4H),1.40(s,9H).
[0187] [13-6] Synthesis of tert-butyl 4-(4-(hydroxymethyl)benzyl)piperazine-1-carboxylate (Compound <13-6>)
[0188] Compound 13-5 (4.37 mmol) obtained in the previous step was added to a 100 mL three-necked flask, and 20 mL of anhydrous tetrahydrofuran was added to dissolve it. The gas in the flask was replaced with nitrogen and connected to a balloon filled with nitrogen. The reaction flask was precooled at -78 °C, and then DIBAL-H 10.9 mL (10.91 mmol, 1 M in THF) was slowly added dropwise. After the addition was completed, the reaction was maintained at -78 °C. After 6 h, TLC detected that the reaction was complete, and H2O was carefully added dropwise to the flask to quench the reaction. The reaction solution condensed into a gel after exothermic reaction. The reaction flask was moved to room temperature, and a sufficient amount of saturated sodium potassium tartrate solution was added until the gel was dissolved, and then extracted with ethyl acetate (3 × 10 mL), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to dryness to obtain compound 13-6, a colorless oily liquid, which can be directly used for the next step. ESI-MS m / z: 307.20 [M + H] + ; 1 H-NMR (600MHz, DMSO-d6) δppm: 7.27 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.2 Hz, 2H), 5.14 (t, J = 5. 7Hz, 1H), 4.48 (d, J = 4.2Hz, 2H), 3.30 (t, J = 5.1Hz, 4H), 2.29 (t, J = 5.1Hz, 4H), 1.39 (s, 9H).
[0189] [13-7] Synthesis of tert-butyl 4-(4-formylbenzyl)piperazine-1-carboxylate (Compound <13-7>)
[0190] The oily compound 13-6 (4.37 mmol) obtained in the previous step was dissolved in 20 mL of dichloromethane, and 3.81 g (43.70 mmol) of activated manganese dioxide powder was added, and the mixture was heated under reflux for 2 h under stirring. TLC detection showed that the reaction was complete, and the manganese dioxide solid was removed by diatomaceous earth filtration. The filtrate was concentrated and separated by silica gel column chromatography (eluent: V 石油醚 / V 乙酸乙酯 =10 / 1) to give compound 13-7, 300 mg, colorless oily liquid, the overall yield of the three-step reaction was 22.56%. ESI-HRMS m / z: 305.1861 [M+H] + ; 1 H-NMR (600MHz, DMSO-d6) δppm: 9.99 (s, 1H), 7.87 (d, J = 7.9Hz, 2H), 7.54 (d, J = 7 .9Hz,2H),3.58(s,2H),3.35-3.28(m,4H),2.32(t,J=5.0Hz,4H),1.39(s,9H).
[0191] [13-8] Synthesis of tert-butyl 4-(4-(((2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxo-1,2,3,4-tetrahydrophthalazin-5-yl)amino)methyl)benzyl)piperazine-1-carboxylate (Compound I-5)
[0192] Weigh 181.63 mg (0.63 mmol) of 13-4 and 287.5 mg (0.95 mmol) of compound 13-7 into a 100 mL round-bottom flask, add 10 mL of anhydrous methanol, stir, some solids dissolve, add 0.5 mL of glacial acetic acid as a catalyst, heat to 50 ° C and react overnight. The next day, the solid in the reaction bottle was completely dissolved, stop heating, cool to room temperature, add 79.18 mg (1.26 mmol) of sodium cyanoborohydride, stir for 8 hours and the reaction is complete. Concentrate the reaction solution, add 20 mL of saturated sodium bicarbonate solution to the residue, bubbles are released, solids are generated, and then extracted with dichloromethane (3×10 mL), combine the organic phases and dry with anhydrous sodium sulfate, filter, concentrate the filtrate and separate it by silica gel column chromatography (eluent is V 二氯甲烷 / V 甲醇 =50 / 1-10 / 1) to give compound I-5, 70 mg, white solid, yield 19.30%. ESI-HRMS m / z: 577.3134 [M+H] + ; 1 H-NMR (600MHz, DMSO-d6) δppm: 10.91 (s, 1H), 7.32 (d, J = 7.8Hz, 2H), 7.25 (d, J = 8.1Hz, 3H), 7.15-7 .08(m,2H),6.69(dd,J=7.5,1.9Hz,1H),6.04(t,J=5.9Hz,1H),5.13(dd,J=12.8,5.3Hz,1H),4.36( d,J=5.9Hz,2H),4.30(d,J=16.3Hz,1H),4.12(d,J=16.3Hz,1H),3.44(s,2H),3.30(s,4H),2.91-2 .79(m,1H),2.61(s,1H),2.47-2.42(m,1H),2.30(s,5H),2.12-2.04(m,1H),1.40(d,J=1.6Hz,9H). 13C-NMR (151MHz, DMSO-d6) δppm: 173.34, 171.65, 163.58, 154.25, 145.39, 139.06, 133.65, 129.44, 128.18, 128.04, 127.52, 127.29, 126.83,121.10,114.99,114.72,79.22,63.19,62.14,58.01,55.38,52.78,51.40,46.67,44.34,31.39,28.52(3C),28.40,22.62.
[0193] Example 14: Synthesis of 3-(3-methyl-5-((4-(morpholinomethyl)benzyl)amino)-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-1)
[0194] The synthesis method was the same as that of Example 13, and the obtained product I-1 was a white solid (130 mg, yield 33.10%). ESI-HRMS m / z: 478.2449 [M+H] + ; 1 H-NMR (600MHz, DMSO-d6) δppm: 10.92 (s, 1H), 7.30 (d, J = 8.0Hz, 2H), 7.24 (d, J = 8.1Hz, 2H), 7.13-7.07 (m, 2H), 6.6 7(dd,J=7.9,1.5Hz,1H),6.04(t,J=6.0Hz,1H),5.12(dd,J=13.0,5.0Hz,1H),4.34(d,J=6.0Hz,2H),4.28(d,J=16. 2Hz,1H),4.10(d,J=16.2Hz,1H),3.55(t,J=4.6Hz,4H),3.41(s,2H),2.84(ddd,J=17.1,13.8,5.4Hz,1H),2.57(d d,J=16.9,3.7Hz,1H),2.49(s,3H),2.43(dd,J=13.3,4.4Hz,1H),2.32(s,4H),2.07(dtd,J=12.7,5.2,2.6Hz,1H). 13C-NMR(151MHz,DMSO-d6)δppm:173.35,171.66,163.59,145.38,139.00,136.62,129.42(2C),128.18,128.04,1 27.26(2C),121.10,114.99,114.73,66.64,62.66,58.01,55.38,53.63(2C),51.40,46.68,44.34,31.39,22.62.
[0195] Example 15: Synthesis of 3-(3-methyl-1-oxo-5-((4-((4-phenylpiperazin-1-yl)methyl)benzyl)amino)-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-3)
[0196] The synthesis method was the same as that of Example 13. The obtained product I-3 was a white solid (90 mg, yield 40.65%). ESI-HRMS m / z: 553.2922 [M+H] + ; 1 H-NMR (600MHz, DMSO-d6) δppm: 10.92 (s, 1H), 7.32 (d, J = 7.8Hz, 2H), 7.27 (d, J = 8.1Hz, 2H), 7.19 (dd, J = 8.7, 7.2Hz, 2H), 7.14-7.08 (m, 2H) ,6.92-6.88(m,2H),6.78-6.74(m,1H),6.68(dd,J=8.0,1.4Hz,1H),6.05(t,J=6.0Hz,1H),5.13(dd,J=12.7,5.0Hz,1H),4.36(d,J=5.9Hz ,2H),4.29(d,J=16.3Hz,1H),4.14-4.09(m,1H),3.48(s,2H),3.17(d,J=5.2Hz,1H),3.11(t,J=5.0Hz,4H),2.84(ddd,J=17.0,13.7,5.3H z,1H),2.57(dd,J=16.7,3.5Hz,1H),2.53-2.52(m,1H),2.47(s,3H),2.46-2.39(m,1H),2.07(dqd,J=12.6,5.0,2.7Hz,1H),1.24(s,2H). 13C-NMR(151MHz,DMSO-d6)δppm:173.35,171.66,163.59,151.49,145.40,139.01,136.89,129.44,129.36(2C),128.19,128.06,127.30(2C) ),126.85,121.11,119.23,115.83(2C),114.99,114.74,62.27,58.02,53.01(2C),51.41,48.64(2C),46.70,44.35,31.39,22.62,22.57.
[0197] Example 16: Synthesis of 3-(5-((4-(4-(4-fluorophenyl)piperazin-1-yl)methyl)benzyl)amino)-3-methyl-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-6)
[0198]
[0199] [16-1] Synthesis of methyl (E)-2-((2-benzylidene-1-methylhydrazine)methyl)-3-nitrobenzoate (Compound <16-1>)
[0200] Weigh 10.50 g (72.84 mmol) of methylhydrazine sulfate and 11.60 g (109.26 mmol) of anhydrous sodium carbonate, suspend in 200 mL of methanol, stir, and heat to 60°C. After 1 hour, add 7.29 mL (72.84 mmol) of benzaldehyde and 20.00 g (72.84 mmol) of methyl 2-bromomethyl-3-nitrobenzoate to the reaction system, and keep stirring at 60°C for 3 hours. After TLC monitoring, filter out the solid after the complete reaction of methyl 2-bromomethyl-3-nitrobenzoate, concentrate the filtrate and chromatograph on a silica gel column (eluent: V 石油醚 / V 乙酸乙酯 =15 / 1) to obtain compound 16-1, 17.0 g, orange-yellow solid, yield 71.1%. ESI-MS m / z: 328.12 [M+H] + .
[0201] [16-2] Synthesis of 3-methyl-5-nitro-3,4-dihydrophthalazin-1(2H)-one (Compound <16-2>)
[0202] Weigh 17.0 g of compound 16-1 (52.00 mmol), add 50 mL of V 正丁醇 / V 冰醋酸= 1 / 1 mixed solvent, stirred until completely dissolved, added anhydrous zinc chloride 354mg (2.60mmol), heated to 120℃ for 6h. Stop heating and stirring, let stand overnight, yellow solid precipitated, filtered, washed with petroleum ether and dried to obtain compound 16-2 (5.90g, yield 54.8%). ESI-HRMS m / z: 206.0560 [M+H] + .
[0203] [16-3] Synthesis of 3-(3-methyl-5-nitro-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound <16-3>)
[0204] 5.00 g of compound 16-2 (24.14 mmol) was weighed and dissolved in 50 mL of anhydrous tetrahydrofuran, and nitrogen was protected. The mixture was stirred in an ice bath and 36 mL of LiHMDs (36.00 mmol, 1N in THF) was added. After the addition was completed, the mixture was stirred in an ice bath for 30 min, and then 6.95 g (36.22 mmol) of 3-bromopiperidine-2,6-dione dissolved in 20 mL of anhydrous tetrahydrofuran was added. The mixture was naturally heated to room temperature and reacted for 3 h. After TLC detection showed that the reaction did not proceed, a saturated ammonium chloride solution was added to the reaction system to quench the reaction, and the liquids were separated. The aqueous phase was extracted with ethyl acetate (3×10 mL), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (the eluent was V 二氯甲烷 / V 甲醇 =50 / 1) to obtain compound 16-3, 4.01 g, white slightly yellow solid, yield 52.10%. ESI-HRMS m / z: 318.3001 [M] + . 1 H-NMR (600MHz, DMSO-d6) δppm: 11.00 (s, 1H), 8.36 (dd, J=8.2, 1.3Hz, 1H), 8.26 (dd, J=7.7, 1.3Hz,1H),7.74(t,J=8.0Hz,1H),5.20(dd,J=12.8,5.1Hz,1H),4.68(d,J=17.2Hz,1H),4. 51(d,J=18.5Hz,1H),2.86(ddd,J=17.2,13.8,5.4Hz,1H),2.60(t,J=4.0Hz,1H),2.57(d,J =3.7Hz,2H),2.45(d,J=10.2Hz,1H),2.43-2.38(m,1H),2.12(ddq,J=10.5,5.3,2.6Hz,1H).
[0205] [16-4] Synthesis of 3-(5-amino-3-methyl-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound <16-4>)
[0206] Weigh 4.00 g (12.58 mmol) of compound 16-3 and add it to 40 mL of methanol. Stir until part of the solid dissolves. Add about 133.86 mg (1.26 mmol) of 5% Pd-C, replace with hydrogen, and then connect a balloon filled with hydrogen. Let the reaction proceed overnight at room temperature. The next day, the solid completely dissolved. TLC detection showed that the reaction was complete. Filter the diatomaceous earth to remove and recover the wet palladium-carbon catalyst. The filtrate was concentrated and purified by silica gel column chromatography (the eluent was V 二氯甲烷 / V 甲醇 =50 / 1-10 / 1) to obtain compound 16-4, 1.21 g, white solid, yield 33.34%. ESI-HRMS m / z: 289.1269 [M+H] + ; 1 H-NMR (600MHz, DMSO-d6) δppm: 10.90 (s, 1H), 7.13-7.06 (m, 2H), 6.86 (dd, J= 7.6,1.5Hz,1H),5.19(s,2H),5.11(dd,J=12.7,5.1Hz,1H),4.18(d,J=16.2Hz ,1H),3.97(d,J=16.2Hz,1H),2.83(ddd,J=17.1,13.8,5.3Hz,1H),2.58-2.5 3(m,1H),2.47(s,3H),2.45-2.37(m,1H),2.05(dtd,J=12.8,5.2,2.6Hz,1H).
[0207] [16-5] Synthesis of tert-butyl 4-(4-fluorophenyl)piperazine-1-carboxylate (Compound <16-5>)
[0208] Weigh 2.00 g (11.43 mmol) of p-bromofluorobenzene, 3.14 g (13.71 mmol) of 1-tert-butyloxycarbonylpiperazine, 30.52 g (0.57 mmol) of Pd2(dba), and 0.82 g (1.72 mmol) of X-Phos into a three-necked flask under nitrogen protection, add 20 mL of anhydrous dioxane, and NaO t Bu 17.2mL (1N in THF), heated to 80℃ for 2h. TLC detection showed that the reaction was complete, and the heating was stopped. The diatomaceous earth was filtered, the filtrate was washed with water, and the liquid was separated. The aqueous phase was extracted with ethyl acetate (2×10mL), the organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and separated by silica gel column chromatography (eluent: V 石油醚 / V 乙酸乙酯=20 / 1) to obtain intermediate 16-5, 2.8 g, yellow oily liquid, yield 87.50%. ESI-MS m / z: 281.17 [M+H] + ; 1 H-NMR (600MHz, DMSO-d6) δppm: 7.05 (dd, J=9.8, 7.9Hz, 2H), 6.98-6.92 (m, 2H), 3.46 (t, J=5.1Hz, 4H), 3.05-2.98 (m, 4H), 1.42 (s, 9H).
[0209] [16-6] Synthesis of 1-(4-fluorophenyl)piperazine (Compound <16-6>)
[0210] Weigh 2.80 g (9.99 mmol) of compound 16-5 and dissolve it in 10 mL of dichloromethane. Add 10 mL of trifluoroacetic acid and stir. React at room temperature for 1 h. TLC detects that the reaction is complete. Evaporate the reaction liquid. Wash the residue with saturated sodium bicarbonate, extract with dichloromethane (2×10 mL). Combine the organic phases and dry with anhydrous sodium sulfate. After filtering, evaporate the filtrate to obtain 1.93 g of crude product 16-6. The yield is 107.34%. Use it directly in the next reaction without purification. ESI-MS m / z: 181.12 [M+H] + ; 1 H-NMR (600MHz, DMSO-d6) δppm: 7.06-7.01 (m, 2H), 6.94-6.89 (m, 2H), 2.98 (s, 1H), 2.97 (d, J = 5.2Hz, 4H), 2.84 (dd, J = 6.2, 3.8Hz, 4H).
[0211] [16-7] Synthesis of 3-(5-((4-(4-(4-fluorophenyl)piperazin-1-yl)methyl)benzyl)amino)-3-methyl-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-6)
[0212] The process of synthesizing compound I-6 from intermediate 16-6 is the same as that of synthesizing compound I-5 from raw material 1-tert-butyloxycarbonylpiperazine in Example 13. The product I-6 is a white solid (110 mg, yield 30.21%). ESI-HRMS m / z: 571.2827 [M+H] + ; 1H-NMR (600MHz, CDCl3) δppm: 8.18 (s, 1H), 7.47 (dd, J=7.8, 1.1Hz, 1H), 7.36 (d, J=7.7Hz, 2H), 7.3 2(d,J=8.1Hz,2H),7.27(d,J=7.9Hz,1H),6.98-6.93(m,2H),6.89-6.84(m,3H),5.23(dd,J=12.4, 5.0Hz,1H),4.35(s,3H),3.91-3.82(m,1H),3.60(s,2H),3.14(t,J=4.9Hz,4H),2.90-2.82(m,1H) ,2.71(ddd,J=17.2,13.6,5.1Hz,2H),2.63(d,J=16.8Hz,8H),2.20(dtd,J=12.9,4.9,2.8Hz,1H). 13 C-NMR (151MHz, DMSO-d6) δppm: 173.35, 171.66, 163.59, 157.21-155.65, 148.40, 145.40, 139.00, 136.88, 129.44 (2C), 128.19, 128.06, 127. 30(2C),121.11,117.57,117.52,115.76,115.62,115.00,114.74,62. 22,58.01,52.99(2C),51.40,49.43(2C),46.70,44.34,31.39,22.62.
[0213] Example 17: Synthesis of 3-(5-((4-(4-(4-cyanophenyl)piperazin-1-yl)methyl)benzyl)amino)-3-methyl-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-7)
[0214] The synthesis method was the same as that of Example 16. The obtained product I-7 was a white solid (80 mg, yield 26.09%). ESI-HRMS m / z: 578.2874 [M+H] + ; 1H-NMR (400MHz, DMSO-d6) δppm: 10.94 (s, 1H), 7.58 (d, J = 8.9Hz, 2H), 7.34 (d, J = 7.9Hz, 2H), 7.29 (d, J = 7.9Hz, 2H), 7.16 -7.08(m,2H),7.04-6.96(m,2H),6.70(dd,J=7.0,2.4Hz,1H),6.07(t,J=6.0Hz,1H),5.15(dd,J=12.6,5.1Hz,1H),4.3 7(d,J=5.9Hz,2H),4.31(d,J=16.2Hz,1H),4.13(d,J=16.4Hz,1H),3.51(s,2H),3.32(s,4H),2.91-2.79(m,1H),2.61( t,J=3.6Hz,1H),2.48(d,J=6.5Hz,3H),2.42(dd,J=13.0,4.9Hz,1H),2.08(dtd,J=11.8,4.6,2.1Hz,1H),1.25(s,2H). 13 C-NMR (151MHz, DMSO-d6) δppm: 173.34, 171.66, 163.60, 153.59, 151.35, 149.70, 145. 40,133.77,129.63,129.38,128.20,128.05,127.55,127.34,121.13,120.54,119.34 ,116.40,115.88,115.01,114.73,114.51,58.02,55.38,51.43,46.70,44.34,40.42,40.28,40.14,40.00,39.86,39.72,39.58,34.19,31.40,29.50,24.99,22.63,14.43.
[0215] Example 18: Synthesis of 3-(5-((4-(4-(3-fluoro-4-cyanophenyl)piperazin-1-yl)methyl)benzyl)amino)-3-methyl-1-oxo-3,4-dihydrophthalazin-2(1H)-yl)piperidine-2,6-dione (Compound I-8)
[0216] The synthesis method was the same as that of Example 16. The obtained product I-8 was a white solid (130 mg, yield 32.55%). ESI-HRMS m / z: 596.2780 [M+H] + ; 1H-NMR (600MHz, DMSO-d6) δppm: 10.92 (s, 1H), 7.58 (t, J = 8.5Hz, 1H), 7.32 (d, J = 7.9Hz, 2H), 7.26 (d, J = 7.9Hz, 2H), 7.14-7.08 ( m,2H),6.92(dd,J=14.2,2.4Hz,1H),6.83(dd,J=9.0,2.4Hz,1H),6.68(dd,J=7.7,1.6Hz,1H),6.05(t,J=6.0Hz,1H),5.13(dd, J=12.7,5.1Hz,1H),4.36(d,J=5.9Hz,2H),4.29(d,J=16.2Hz,1H),4.11(d,J=16.3Hz,1H),3.48(s,2H),3.36(t,J=5.0Hz,4H) ,2.84(ddd,J=17.0,13.8,5.3Hz,1H),2.57(dt,J=17.1,3.7Hz,1H),2.44(t,J=5.4Hz,5H),2.07(dtd,J=12.8,5.2,2.6Hz,1H). 13 C-NMR(151MHz,DMSO-d6)δppm:173.35,171.66,165.53-163.88,163.59,15 5.67,155.60,145.38,139.12,134.42,134.40,129.46,128.19,128.04,12 7.32,121.11,115.89,115.00,114.74,110.54,100.69,100.53,86.48,86. 38,61.99,58.02,55.38,52.42,51.40,46.72,46.69,44.35,31.39,22.62.
[0217] Example 19: Evaluation of the Anti-Proliferation Activity of Compounds against Multiple Myeloma NCI-H929 and RPMI-8226 Cells
[0218] The cell models used in this example are human multiple myeloma NCI-H929 and RPMI-8226 cells, and the proliferation inhibitory activities of some compounds of the present invention on NCI-H929 and RPMI-8226 cells are measured.
[0219] 1. Experimental materials and instruments
[0220] 1.1 Experimental Materials and Instruments
[0221]
[0222]
[0223] 2. Experimental steps
[0224] (1) Solution preparation
[0225] ① Dissolve the selected compounds in DMSO to prepare a 10 mM stock solution. Compounds used within three months should be stored in a desiccator at room temperature, and others can be stored at -20°C for a long term.
[0226] ② The above compound stock solutions and the positive reference compound pomalidomide were diluted with DMSO, with a starting concentration of 10 μM. In the NCI-H929 and RPMI-8226 cell experiments, 3-fold gradient dilutions were performed, with 11 concentration points, and the lowest concentration was 0.00047 μM. Oscillate on an oscillator for 5 minutes.
[0227] (2) Cell dosing
[0228] ① NCI-H929 and RPMI-8226 cells in the logarithmic growth phase were seeded in 96-well plates, with 20,000-30,000 cells per well, and the culture plates were pre-cultured in an incubator for 24 hours (under the conditions of 37° C. and 5% CO 2 ).
[0229] ② Replace the culture medium in the well plate and add 50 μl of the corresponding concentration of compound and positive control to the culture plate.
[0230] ③ Incubate the culture plate in an incubator for 144 hours, add 15 μl of CCK-8 solution to each well, and then incubate the culture plate in an incubator for 1-4 hours.
[0231] ④Measure the absorbance at 450nm using an enzyme-labeled instrument.
[0232] (3) Data processing
[0233] ① Calculate %Inhibition:
[0234] %Inhibition=100-(Signalcmpd-SignalAve_PC) / (SignalAve_VC-SignalAve_PC)×100.
[0235] ②Calculate the IC of the compound 50 And Plot effect dose curve:
[0236] IC was calculated by fitting the logarithm of %Inhibition and compound concentration to a nonlinear regression (dose response - variable slope) using GraphPad 6.0. 50 value.
[0237] Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)*HillSlope))
[0238] X: log of inhibitor concentration; Y: %Inhibition.
[0239] 3. Experimental results
[0240] After calculating %Inhibition, a dose-effect curve was drawn with the logarithm of the test compound concentration as the abscissa and the average cell survival rate as the ordinate, and the IC 50 value.
[0241] The test results of the above compounds and the positive reference compound Pomalidomide on NCI-H929 and RPMI-8226 cells are shown in Table 1. The experimental results show that compounds I-2, I-4, I-5, I-6, I-7, and I-8 significantly inhibit the proliferation of H929 cells, and the inhibitory effect is better than the control drug Pomalidomide. In RPMI8226 cells, compounds I-7 and I-8 significantly inhibit the proliferation of RPMI-8226 cells, and the inhibitory effect is better than the control drug Pomalidomide.
[0242] Table 1. Antiproliferative activity of compounds against NCI-H929 and RPMI-8226 cells (IC 50 value)
[0243]
[0244]
[0245] ND: Not detected. The IC values of compounds with inhibition rates less than 50% at 10 μM concentration were not fitted. 50 value.
[0246] Example 20: In vivo activity of the compound against human multiple myeloma RPMI-8226 transplanted tumors
[0247] In this example, the cell model selected was human multiple myeloma RPMI-8226 cell line, and the inhibitory effect of the compound on the growth of RPMI-8226 tumor cell NOD / SCID mouse transplanted tumor was determined. The evaluation method and results are described below.
[0248] 1. Experimental Materials and Instruments
[0249] 1.1 Experimental consumables for biological activity evaluation
[0250]
[0251] 2. Establishment of Tumor Model
[0252] Human multiple myeloma RPMI-8226 was routinely cultured in RPMI1640 containing 10% fetal bovine serum at 37°C in a 5% CO2 incubator. After three generations in vitro, when the cells grew to more than 80% and the fusion rate reached the required amount, the cells were digested and collected, washed with PBS and counted, and the cell concentration was adjusted to about 5×10 7 Place the 500 μg / mL in a 4 mL centrifuge tube and place on ice for later use.
[0253] Female NOD / SCID mice aged 4 to 5 weeks were selected and inoculated subcutaneously with RPMI-8226 cells. The mice were grasped and placed on their side. The axilla of the forelimbs was disinfected with 75% alcohol. 100 μL of cell suspension was drawn with a 1 mL syringe and injected into the axilla subcutaneously, i.e., 1.5×10 7 cells / mouse / 100μL.
[0254] 3. Experimental Animal Grouping and Drug Administration
[0255] When the tumor grows to 90-150 mm 3 Afterwards, the animals were randomly divided into groups, 8 in each group, and fed according to different dosing forms, namely:
[0256] Model control group: gavage with the same volume of blank solvent (DMSO: 0.5% sodium carboxymethyl cellulose: distilled water = 1:1:8) every day;
[0257] Test group: 10 mg / kg (mouse body weight) of compound I-4, I-8 solution was intragastrically administered every day.
[0258] Positive control group: Pomalidomide solution of 10 mg / kg (mouse body weight) was intragastrically administered every day.
[0259] The administration route was oral gavage, and the administration frequency was once a day for 12 consecutive days. The first day of administration was defined as the first day of the experiment. The changes in the tumor volume of the mice were measured and recorded every two days. Tumor volume was measured using a vernier caliper to measure the long diameter (a) and short diameter (b) of the tumor and calculate the tumor volume. The tumor volume V (mm 3 ) = axb^ 2 / 2. After the experiment, the mice were dissected and the tumor weight was weighed. The data were entered and statistically analyzed using GraphPad Prism 6 software. The data were expressed as mean±SEM (Standard Error of Mean, standard error), and one-way ANOVA was used. P≤0.05 was considered statistically significant.
[0260] 4. Experimental Results
[0261] like Figure 1 As shown in Figures A and B and Table 2, the experimental results show that compounds I-4 and I-8 (10 mg / kg) significantly inhibited the growth of RPMI-8226 transplanted tumors. At the same dose, the inhibitory effects of I-4 and I-8 on tumor growth were better than those of the positive drug Pomalidomide. Figure 1 As shown in C, the body weight of mice in each group did not change significantly during the experiment, and no obvious toxic side effects were observed during the experiment.
[0262] Table 2. Inhibitory effects of compounds I-4 and I-8 on human multiple myeloma RPMI-8226 xenograft tumors
[0263]
[0264] Example 21: In vivo activity of the compound against human multiple myeloma NCI-H929 transplanted tumors
[0265] In this example, the cell model selected was human multiple myeloma NCI-H929 cell line, and the inhibitory effect of the compound on the growth of NCI-H929 tumor cell NOD / SCID mouse transplanted tumor was determined. The evaluation method and results are described below.
[0266] 1. Experimental Materials and Instruments
[0267] 1.1 Experimental consumables for biological activity evaluation
[0268]
[0269]
[0270] 2. Establishment of Tumor Model
[0271] Human multiple myeloma NCI-H929 cells were routinely cultured in RPMI1640 containing 10% fetal bovine serum at 37°C in a 5% CO2 incubator. After three generations in vitro, when the cells grew to more than 80% and the fusion rate reached the required amount, the cells were digested and collected, washed with PBS and counted, and the cell concentration was adjusted to about 5×10 7 Place the 500 μg / mL in a 4 mL centrifuge tube and place on ice for later use.
[0272] Female NOD / SCID mice aged 4 to 5 weeks were selected and inoculated subcutaneously with NCI-H929 cells. The mice were grasped and placed on their side. The axilla of the forelimbs was disinfected with 75% alcohol. 100 μL of cell suspension was drawn with a 1 mL syringe and injected into the axilla subcutaneously, i.e., 1.5×10 7 cells / mouse / 100μL.
[0273] 3. Experimental Animal Grouping and Drug Administration
[0274] When the tumor grows to 90-150 mm 3 Afterwards, the animals were randomly divided into groups, 8 in each group, and fed according to different dosing forms, namely:
[0275] Model control group: gavage with the same volume of blank solvent (DMSO: 0.5% sodium carboxymethyl cellulose: distilled water = 1:1:8) every day;
[0276] Control drug group 1: Pomalidomide solution of 10 mg / kg (mouse body weight) was intragastrically administered daily;
[0277] Control drug group 2: daily intragastric administration of 3 mg / kg (mouse body weight) of CC-220 solution;
[0278] Control drug group 3: daily intragastric administration of 10 mg / kg (mouse body weight) of CC-220 solution;
[0279] Experimental compound group 4: 3 mg / kg (mouse body weight) of compound I-4 solution was intragastrically administered every day;
[0280] Experimental compound group 5: 10 mg / kg (mouse body weight) of compound I-4 solution was intragastrically administered every day;
[0281] Experimental compound group 6: 3 mg / kg (mouse body weight) of compound I-8 solution was intragastrically administered daily;
[0282] Experimental compound group 7: intragastrically administered 10 mg / kg (mouse body weight) of I-8 solution every day;
[0283] The administration route was oral gavage, and the administration frequency was once a day for 10 consecutive days. The first day of administration was defined as the first day of the experiment. The changes in the tumor volume of the mice were measured and recorded every two days. Tumor volume was measured using a vernier caliper to measure the long diameter (a) and short diameter (b) of the tumor and calculate the tumor volume. The tumor volume V (mm 3 ) = axb^ 2 / 2. After the experiment, the mice were dissected and the tumor weight was weighed. The data were entered and statistically analyzed using GraphPad Prism 6 software. The data were expressed as mean±SEM (Standard Error of Mean, standard error), and one-way ANOVA was used. P≤0.05 was considered statistically significant.
[0284] 4. Experimental Results
[0285] like Figure 2As shown in Figure A and Table 3, the experimental results show that compounds I-4 and I-8 (3 mg / kg and 10 mg / kg) significantly inhibited the growth of NCI-H929 transplanted tumors. At the same dose, I-4 and I-8 (10 mg / kg) had significantly better inhibitory effects on tumor growth than the control drug Pomalidomide (10 mg / kg). At the same dose, I-8 (3 mg / kg) was better than the control drug CC-220 (3 mg / kg). Figure 2 As shown in B, during the experiment, the body weight of the CC-220 (10 mg / kg) group showed a downward trend, while the other groups did not show an obvious trend of weight loss, and no obvious toxic side effects were observed.
[0286] Table 3. Inhibitory effects of compounds I-4 and I-8 on human multiple myeloma NCI-H929 xenograft tumors
[0287]
[0288] Example 22: In vivo anti-tumor activity of the compound combined with dexamethasone against human multiple myeloma NCI-H929 transplanted tumors
[0289] In this example, the cell model selected human multiple myeloma NCI-H929 cell line was used to measure the inhibitory effects of the compound and dexamethasone alone and in combination on the growth of NCI-H929 tumor cell NOD / SCID mouse transplanted tumors. The evaluation method and results are described below.
[0290] 1. Experimental Materials and Instruments
[0291] 1.1 Experimental consumables for biological activity evaluation
[0292]
[0293]
[0294] 2. Establishment of Tumor Model
[0295] Human multiple myeloma NCI-H929 cells were routinely cultured in RPMI1640 containing 10% fetal bovine serum at 37°C in a 5% CO2 incubator. After three generations in vitro, when the cells grew to more than 80% and the fusion rate reached the required amount, the cells were digested and collected, washed with PBS and counted, and the cell concentration was adjusted to about 5×10 7 Place the 500 μg / mL in a 4 mL centrifuge tube and place on ice for later use.
[0296] Female NOD / SCID mice aged 4 to 5 weeks were selected and inoculated subcutaneously with NCI-H929 cells. The mice were grasped and placed on their side. The axilla of the forelimbs was disinfected with 75% alcohol. 100 μL of cell suspension was drawn with a 1 mL syringe and injected into the axilla subcutaneously, i.e., 1.5×10 7 cells / mouse / 100μL.
[0297] 3. Experimental Animal Grouping and Drug Administration
[0298] When the tumor grows to 90-150 mm 3 Afterwards, the animals were randomly divided into groups, 8 in each group, and fed according to different dosing forms, namely:
[0299] Model control group: gavage with the same volume of blank solvent (DMSO: 0.5% sodium carboxymethyl cellulose: distilled water = 1:1:8) every day;
[0300] Test group 1: 3 mg / kg (mouse body weight) of dexamethasone (Dex) solution was intragastrically administered daily;
[0301] Test group 2: 3 mg / kg (mouse body weight) of I-4 solution was intragastrically administered daily;
[0302] Test group 3: gavage of 3 mg / kg (mouse body weight) of I-8 solution every day;
[0303] Test group 4: 3 mg / kg (mouse body weight) of dexamethasone and 3 mg / kg (mouse body weight) of I-4 solution were intragastrically administered daily;
[0304] Test group 5: daily intragastric administration of 3 mg / kg (mouse body weight) of dexamethasone and 3 mg / kg (mouse body weight) of I-8 solution;
[0305] The administration route was oral gavage, and the administration frequency was once a day for 10 consecutive days. The first day of administration was defined as the first day of the experiment. The changes in the tumor volume of the mice were measured and recorded every two days. Tumor volume was measured using a vernier caliper to measure the long diameter (a) and short diameter (b) of the tumor and calculate the tumor volume. The tumor volume V (mm 3 ) = axb^ 2 / 2. After the experiment, the mice were dissected and the tumor weight was weighed. The data were entered and statistically analyzed using GraphPad Prism 6 software. The data were expressed as mean±SEM (Standard Error of Mean, standard error), and one-way ANOVA was used. P≤0.05 was considered statistically significant.
[0306] 4. Experimental Results
[0307] like Figure 3As shown in Table 4, the experimental results show that compounds I-4 and I-8 (3 mg / kg) alone effectively inhibit the growth of NCI-H929 transplanted tumors, and dexamethasone (3 mg / kg) has a weaker ability to inhibit tumors. The combination of I-4 (3 mg / kg) and dexamethasone (3 mg / kg) significantly inhibits the growth of NCI-H929 transplanted tumors. At the same time, the inhibitory effects of I-4 (3 mg / kg) and I-8 (3 mg / kg) combined with dexamethasone (3 mg / kg) are significantly better than those of single drugs, showing a significant combined effect.
[0308] Table 4. Inhibitory effects of compounds I-4 and I-8 on human multiple myeloma NCI-H929 xenograft tumors
[0309]
[0310]
[0311] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. It should be pointed out that a person skilled in the art can make several improvements and modifications without departing from the technical principles of the present invention, and these improvements and modifications should also be regarded as within the scope of protection of the present invention.
Claims
1. A compound represented by formula (I) or a pharmaceutically acceptable salt or isomer thereof: in: X1 is CH; n is 2; R1 is selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl; S / D is a single bond; R2 is H; R3 is -NR4R5; R4 and R5 together with the atoms to which they are attached form a structure as shown in formula (II), in, X2 is NH; Ring A is a benzene ring; R7 is selected from H, D and halogen; R8 is a structure represented by formula (III): in, Ring B is a substituted piperazine represented by formula (IV), in, Ring C is a benzene ring; R 14 is H, D, halogen, cyano, nitro or hydroxy; n' = 0, 1, 2, 3, 4 or 5; R 12 is H, D or halogen.
2. The compound according to claim 1 or its pharmaceutically acceptable salt or isomer, wherein: R1 is CH3.
3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt or isomer thereof, wherein: (a) R7 is H; (b)R 14 is H, halogen or cyano; (c)R 12 For H.
4. The following compounds or their pharmaceutically acceptable salts or isomers, wherein: The compound is selected from:
5. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt or isomer thereof, and one or more pharmaceutically acceptable carriers or excipients.
6. The pharmaceutical composition according to claim 5, wherein The pharmaceutically acceptable carrier or excipient is selected from ion exchangers, alumina, aluminum stearate, lecithin, serum protein, buffer substances, water, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose substances, polyethylene glycol, polyacrylates, beeswax and lanolin.
7. The pharmaceutical composition according to claim 6, wherein The serum protein is human albumin.
8. The pharmaceutical composition according to claim 6, wherein The buffer substance is a mixture of glycerol, sorbic acid, potassium sorbate and a partial glyceride of saturated vegetable fatty acids.
9. The pharmaceutical composition according to claim 6, wherein The cellulose material is sodium carboxymethyl cellulose.
10. A combination drug comprising the compound of any one of claims 1 to 4 or a pharmaceutically acceptable salt, isomer thereof and at least one additional drug, wherein the at least one additional drug is a chemotherapeutic agent or an immunomodulator.
11. The combined drug according to claim 10, wherein The chemotherapeutic agent or immunomodulator is selected from immune checkpoint inhibitors, tyrosine kinase inhibitors, proteasome inhibitors, antibiotics, alkylating agents, antimetabolites, hormones, immunoactive agents, interferon-type active agents and mixed active agents.
12. The compound according to any one of claims 1 to 4 or its pharmaceutically acceptable salt, isomer or the pharmaceutical composition according to any one of claims 5 to 9 or the combined drug according to claim 10 or 11 in the preparation of a drug for treating and / or preventing CRL4 CRBN Use of drugs in E3 ubiquitin ligase-related diseases.
13. The use according to claim 12, wherein The disease is pain.
14. The use according to claim 12, wherein The disease is selected from cancer, a nervous system disease and an immune system disease.
15. The use according to claim 14, wherein The cancer disease is digestive tract cancer.
16. The use according to claim 14, wherein The cancer disease is skin cancer.
17. The use according to claim 14, wherein The cancer disease is endocrine gland cancer.
18. The use according to claim 14, wherein The cancer disease is one or more of leukemia, multiple myeloma, malignant lymphoma, myelodysplastic syndrome, breast cancer, lung cancer, liver cancer, pancreatic cancer, head and neck cancer, melanoma, uterine cancer, ovarian cancer, kidney or ureter cancer, and CNS tumors.
19. The use according to claim 18, wherein The malignant lymphoma is selected from the group consisting of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma and Waldenstrom's macroglobulinemia.
20. The use according to claim 14, wherein The immune system disease is erythema nodosum.
21. The use according to claim 14, wherein The immune system disease is an autoimmune disease.
22. The use according to claim 21, wherein The autoimmune disease is systemic lupus erythematosus.
23. The compound of any one of claims 1-4 or its pharmaceutically acceptable salt, isomer or the pharmaceutical composition of any one of claims 5-9 or the combination drug of claim 10 or 11, administered by a suitable route, wherein the suitable route is oral, sublingual, rectal, parenteral, injection, pulmonary, nasal, tongue, buccal, skin, mucosa, conjunctiva, topical administration or administration in the form of an implant.
24. The compound according to any one of claims 1 to 4 or its pharmaceutically acceptable salt, isomer or the pharmaceutical composition according to any one of claims 5 to 9 or the combination drug according to claim 10 or 11, administered by a suitable route, wherein the suitable route is intradermal, subcutaneous, intramuscular, intravenous or arterial injection.
25. The compound according to any one of claims 1 to 4 or its pharmaceutically acceptable salt or isomer as CRL4 CRBN Use of ligands of E3 ubiquitin ligase in preparing protein targeted degraders.
